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LF Moriarty
ABSTRACT
Epidemiology of malaria and other diseases of public health importance and implications for
interventions in high transmission settings in sub-Saharan Africa
by
Leah F. Moriarty
November 11, 2020
Infectious diseases remain a major cause of disability of death in low-resource settings. Malaria alone was
responsible for an estimated 405,000 deaths globally in 2018, with the 94% of these deaths occurring in
sub-Saharan Africa. In Mozambique and Democratic Republic of the Congo (DRC), communicable
diseases, including malaria, lower respiratory infections, and neonatal disorders are among the top causes
of disability and death. Understanding malaria and co-endemic diseases in these two countries can aid the
planning, evaluation, and targeting of public health interventions. Additionally, studying the efficacy of
the drugs used to treat malaria will preserve the ability for malaria cases to be treated successfully.
The three studies in this dissertation describe the epidemiology of malaria and co-endemic diseases of
public health importance in Mozambique and evaluate the efficacy of medicines used to treat malaria in
DRC. The first study will describe the spatial epidemiology of malaria in two high-burden districts in
northern Mozambique to explore the utility of exploration of local spatial heterogeneity in hightransmission settings. The second study will investigate patterns in antibody responses to several
infectious pathogens of public health importance in Mozambique, providing an opportunity to understand
common predictors of infectious diseases endemic in this region. The third study will examine the
efficacy of three artemisinin-based combination therapies used to treat uncomplicated malaria and
molecular markers of antimalarial resistance in five sites in DRC.
Collectively, the three studies in this dissertation describe factors that have implications for intervention
planning and disease surveillance in areas with high malaria and other tropical disease burden and limited
health resources. Careful consideration of transmission setting can support more efficient and higher
quality data collection and may allow for intervention design tailored to the local realities that can target
multiple diseases of public health importance.

1 of 107

LF Moriarty
Epidemiology of malaria and other diseases of public health importance and implications for
interventions in high transmission settings in sub-Saharan Africa
by
Leah Frankel Moriarty
Bachelor of Arts in Psychology
American University, 2009
Master of Public Health in Global Health
Emory University, 2014

A Dissertation Submitted to the Graduate Faculty of Georgia State University in Partial Fulfillment of the
Requirements for the Degree
DOCTOR OF PHILOSOPHY IN PUBLIC HEALTH

ATLANTA, GEORGIA
30303

2 of 107

LF Moriarty
APPROVAL PAGE
Epidemiology of malaria and other diseases of public health importance and implications for
interventions in high transmission settings in sub-Saharan Africa
by
Leah Frankel Moriarty

Gerardo Chowell
Committee Chair

Richard Rothenberg
Committee Member

Mateusz Plucinski
Committee Member

November 11, 2020

3 of 107

LF Moriarty
Acknowledgements

I applied for this degree program while responding to the 2014 West Africa Ebola Virus Disease epidemic
and am completing it during the COVID-19 pandemic. These bookends underscore critical role of
epidemiologists in this world and the mentors that guide us through the education and real-world
experience needed to protect the public from health threats. I thank the mentors who encouraged me to
pursue this degree, guided me through this degree, and taught me how to be a mentor for future scholars.

The other constant throughout this process has been my family, Ryan and Nafi, thank you for your
unconditional support.

4 of 107

LF Moriarty
Author’s Statement Page

In presenting this dissertation as a partial fulfillment of the requirements for an advanced degree
from Georgia State University, I agree that the Library of the University shall make it available for
inspection and circulation in accordance with its regulations governing materials of this type. I agree that
permission to quote from, to copy from, or to publish this dissertation may be granted by the author or, in
his/her absence, by the professor under whose direction it was written, or in his/her absence, by the
Associate Dean, School of Public Health. Such quoting, copying, or publishing must be solely for scholarly
purposes and will not involve potential financial gain. It is understood that any copying from or publication
of this dissertation which involves potential financial gain will not be allowed without written permission
of the author.

11/17/2020

X
Leah F. Moriarty
Signed by: PIV

5 of 107

LF Moriarty

Table of Contents
List of Tables ................................................................................................................................................ 8
List of Figures ............................................................................................................................................... 9
Chapter 1: Literature review and statement of purpose .............................................................................. 10
Introduction ............................................................................................................................................. 10
Review of the Literature ......................................................................................................................... 12
Statement of purpose............................................................................................................................... 18
Works cited ............................................................................................................................................. 20
Chapter 2: An exploratory spatial analysis of malaria in two high-burden districts in Mozambique ......... 25
Background ............................................................................................................................................. 28
Methods .................................................................................................................................................. 29
Results ..................................................................................................................................................... 33
Discussion ............................................................................................................................................... 37
Limitations .............................................................................................................................................. 39
Conclusions ............................................................................................................................................. 39
Works Cited ............................................................................................................................................ 40
Declarations ............................................................................................................................................ 43
Chapter 3: Investigation of patterns of antibody responses to infectious diseases using multiplex serology
in Nampula, Mozambique ........................................................................................................................... 44
Abstract ................................................................................................................................................... 45
Introduction ............................................................................................................................................. 46
Methods .................................................................................................................................................. 47
Ethical Considerations ............................................................................................................................ 52
Results ..................................................................................................................................................... 52
Discussion ............................................................................................................................................... 59
Limitations .............................................................................................................................................. 61
Conclusions ............................................................................................................................................. 61
Funding information ............................................................................................................................... 61
Declarations ............................................................................................................................................ 62
Works cited ............................................................................................................................................. 62
Chapter 4: Decreased efficacy of artemisinin-based combination therapies in Democratic Republic of the
Congo and investigation of molecular markers of antimalarial resistance ................................................. 65
Abstract ................................................................................................................................................... 66
Introduction ............................................................................................................................................. 67
6 of 107

LF Moriarty
Methods .................................................................................................................................................. 67
Ethical considerations ............................................................................................................................. 72
Results ..................................................................................................................................................... 74
Discussion ............................................................................................................................................... 83
Limitations .............................................................................................................................................. 83
Recommendations and conclusions ........................................................................................................ 84
Declarations ............................................................................................................................................ 85
Works cited ............................................................................................................................................. 86
Chapter 5: Dissertation Summary and Future Directions in Research........................................................ 88
Summary ................................................................................................................................................. 88
Directions for future research ................................................................................................................. 89
Appendix: Supplemental Tables & Figures ................................................................................................ 90

7 of 107

LF Moriarty

List of Tables
Table 1.1: Summary of study sample of malaria RDT positivity in two districts in Nampula Province,
Mozambique, 2014
Table 1.2: Hotspots and coldspots of P. falciparum rapid diagnostic test identified using spatial scan
statistics in two districts of Nampula province, Mozambique, 2014
Table 2.1: Antigens and corresponding infectious agents measured in Mozambique household survey,
2014
Table 2.2: Characteristics of sample of household survey conducted in 2 districts of Nampula
Mozambique, 2014
Table 2.3: Variables included in linear regression models regressing covariates on log-MFI for 39
antigens, Nampula, Mozambique, 2014
Table 3.1: Baseline characteristics and enrollment of patients participating in the DRC therapeutic
efficacy study, 2017
Table 3.2: Classification of patients with the outcome of late recurrence, DRC therapeutic efficacy study,
2017
Table 3.3: Therapeutic efficacy of three artemisinin-based combination therapies at five monitoring sites,
Democratic Republic of the Congo, 2017
Table 3.4: Molecular markers of resistance, all drug arms, Democratic Republic of the Congo therapeutic
efficacy study, 2017
Supplemental Table 2.1: Protein amounts & buffer conditions used for the analysis of 39 antigens plus
one control
Supplemental Table 3.1: Molecular markers of resistance and association with treatment outcome,
artemether lumefantrine arms, DRC therapeutic efficacy study, 2017
Supplemental Table 3.2: Molecular markers of resistance and association with treatment outcome,
artesunate-amodiaquine arms, Democratic Republic of the Congo therapeutic efficacy study, 2017
Supplemental Table 3.3: Molecular markers of resistance and association with treatment outcome,
dihydroartemisinin-piperaquine arms, Democratic Republic of the Congo therapeutic efficacy study, 2017

8 of 107

LF Moriarty

List of Figures
Figure 1.1: Location of households included in sample and malaria rapid diagnostic test (RDT) results in
Mecúburi and Nacala-a-Velha, Nampula Province, Mozambique
Figure 1.2: Moran’s I statistic for global spatial autocorrelation of proportion of household members
testing positive for malaria by rapid diagnostic test over 10 distance classes in Nampula Province,
Mozambique, 2014
Figure 1.3: Difference in K Functions between households with at least one positive P. falciparum malaria
rapid diagnostic test and households with only negative P. falciparum rapid diagnostic tests in two
districts in Nampula Province, Mozambique
Figure 2.1: Density plots of Log MFI values by antigen, Nampula Mozambique household survey, 2014
Figure 2.2: Matrix of Pearson correlation coefficients and p-values of adjusted log-MFI for 40 antigens
measured using a multiplex bead assay, Nampula, Mozambique, 2014
Figure 3.1: Location of antimalarial therapeutic efficacy monitoring sites, Democratic Republic of the
Congo, 2017
Supplemental Figures 2.1 – 2.7: Density plots by age group of log-MFI values by antigen, Nampula,
Mozambique 2014
Supplemental Figure 3.1: Multiplicity of infection of day 0 and day of recurrence samples from
recurrences as determined by the maximum number of alleles detected among seven neutral microsatellite
markers, Democratic Republic of the Congo therapeutic efficacy study, 2017
Supplemental Figure 3.2: Histogram of posterior probability of recrudescence of all late recurrences for
which the probability of recrudescence is over 0% (n=114)
Supplemental Figure 3.3: Assessment of the use of different cutoffs of posterior probability of
recrudescence derived using a Bayesian algorithm for interpreting microsatellite data for molecular
correction, Democratic Republic of the Congo therapeutic efficacy study, 2017

9 of 107

LF Moriarty

Chapter 1: Literature review and statement of purpose
Introduction
Malaria
Malaria is a disease caused by the parasite belonging to the genus Plasmodium. Five species are known
infect humans: P. falciparum (the most common and associated with the highest mortality), P. vivax, P.
ovale, and P. malariae, and more recently P. knowlesi 1,2. The epidemiology of P. falciparum in central
and southern Africa is well documented3,4, and there is evidence that P. vivax, P. ovale, and P. malariae
are also circulating5–7.
Malaria is transmitted through the female Anopheles mosquito, of which there are 30 species are
implicated in malaria transmission8. Malaria transmission is affected by mosquito breeding and feeding
behavior and survival, which are affected by climatic conditions such as rainfall, altitude, and
temperature. While Anopheles behavior is diverse, most species tend to be active at dusk2. In central and
southern Africa, Anopheles arabiensis and funestus have been found to be common malaria vectors9,10.
Symptoms of uncomplicated malaria are non-specific; the main symptom is fever and can also include
chills, sweats, headaches, muscle pain, nausea, and vomiting11. Clinical symptoms of severe malaria, most
commonly caused by P. falciparum, include impaired consciousness, respiratory distress, convulsions,
coma, shock, pulmonary edema, bleeding, and jaundice12.
The gold standard for the diagnosis of malaria in a clinical setting has historically been blood film
microscopy where blood is taken from an individual who has suspected malaria, spread on a blood smear
stained with Giemsa and read by a microscopist trained to diagnose and distinguish parasite species2.
Malaria rapid diagnostic tests (RDTs) have increased the accessibility of malaria diagnostics to people
without access to a healthcare structure with microscopy among its services. The RDT requires a few
drops of capillary blood that are mixed with a lysing agent in a plastic test strip, which detects the target
antigen in the blood, providing easily interpretable results within about 20 minutes. The RDT is widely
used at the peripheral levels of the healthcare system, including at the community level. There are several
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types of malaria RDTs, many of which are single species for P. falciparum and some of which are
multispecies13. Other diagnostic tools for malaria outside the point of care setting include molecular
methods, which are highly sensitive and can detect low density infection as well as be used to identify
malaria species14. Evidence of recent or past exposure to malaria can be detected using serological tests,
for which blood samples are taken and tested for a quantifiable reaction to species-specific antigens15.
Serological studies can be helpful in a household survey setting, where the goal is to learn about how the
population has been affected by malaria rather than how much of the population has active malaria
infection16.
To treat uncomplicated malaria, the World Health Organization (WHO) recommends the use of
artemisinin-based combination therapy (ACT), a type of medication containing an artemisinin derivative,
which works quickly to reduce initial parasitemia, and a partner drug that works to clear remaining
parasitemia and prevent the emergence of artemisinin resistance. There are six ACTs recommended by
WHO for the treatment of uncomplicated malaria17,18.
Additional infectious diseases of public health importance
Infectious diseases remain a major cause of disability of death in low-resource settings. Malaria alone was
responsible for an estimated 405,000 deaths globally in 2018, with the 94% of these deaths occurring in
sub-Saharan Africa4. WHO estimates that 96 million people become ill and 40,000 people die from
Dengue infection each year19. Local transmission and periodic outbreaks of Chikungunya and Rift Valley
Fever are reported throughout sub-Saharan Africa20,21. Lymphatic filariasis, a parasitic infection also
transmitted by mosquitoes that can cause elephantiasis, infects an estimated 51 million people
worldwide22.
Despite tremendous gains in implementing childhood vaccination programs throughout sub-Saharan
Africa, there is evidence that high coverage of basic childhood vaccinations has not reached the entire
continent, resulting avoidable morbidity and mortality, notably among children23–25. Diarrhea also remains
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a significant cause of disease and death, also disproportionately affecting young children. Rotavirus,
Cryptosporidium spp., and Shigella spp., Escherichia coli, and salmonella have been found to be
significant causes of severe diarrheal illness and death in low-income regions26,27.
Finally, neglected tropical diseases (NTDs), a group of illnesses representing bacterial, parasitic, viral,
and fungal etiologies associated with poverty, are significant causes of disability with debilitating
physical, economic, and social impact on the afflicted individuals and communities28.
Mozambique & Democratic Republic of the Congo (DRC)
Communicable, maternal, neonatal and nutritional diseases have remained the most common cause of
disability and death in Mozambique. Under five mortality was an estimated 73.8 per 1,000 live births as
of 2017. In DRC, malaria, lower respiratory infections, and neonatal disorders cause the most deaths and
disability, and under five mortality was an estimated 81.9 per 1,000 live births in 2017. Mozambique and
DRC are among the countries with the highest rates of child mortality in the world29.
Mozambique and DRC are among six countries worldwide that accounted for over half of all malaria
cases in 2018. DRC accounts for 11% and Mozambique accounts for 4% of malaria deaths globally4.
Both countries are part of a new WHO initiative called “High Burden High Impact” that seeks to reduce
the impact of malaria in the highest burden countries. In Mozambique, malaria is responsible for 42% of
deaths among children under five years old. All 29.7 million persons living in Mozambique are at risk for
malaria, but the burden of disease is highest in the center and northern of the country, particularly the
provinces of Nampula and Zambézia30,31. In DRC, malaria is responsible for 19% of deaths among
children under five years old, and 100% of the population of 81.3 million persons is at risk for malaria,
and the highest burden provinces include Bas-Congo, Orientale, and Kasai Oriental3.
Review of the Literature
Spatial epidemiology of malaria
The method of transmission and therefore its predictors are associated with location, increasing the
likelihood of a spatially nonrandom distribution of the malaria in endemic areas. Spatially nonrandom
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predictors include Anopheles breeding sites and their proximity to humans, housing materials and type,
occupation as well as environmental variables including rainfall and altitude32–36. There are several
methods available to detect and quantify spatial autocorrelation and used to describe malaria
epidemiology with differing assumptions, methods, and nuances. Understanding the spatial epidemiology
of malaria using methods that are practical and interpretable will assist public health practitioners to
design interventions targeting the most at-risk areas and people.
The most common method used to identify clusters of infectious diseases, including malaria in a given
area is the use of Kulldorff’s spatial scan statistic, or SatScan. This method uses geographic point data to
detect whether the outcome of interest is distributed randomly over space and detects clusters and assigns
statistical significance to them. The general null hypothesis is that the outcome of interest is uniformly
distributed across space. The SatScan statistic can use one of two models: a Poisson-based model, for
count data and a Bernoulli model for case/non-case data37. To detect clusters, an area is scanned gradually
with a predefined circular window size for which the radius of which can be up to 50% of the area of
interest, or by a pre-defined radius size. For malaria, researchers have chosen varying pre-defined sizes,
many correlating with the farthest distance traveled by the Anopheles mosquito38. At each window, the
number of observed and expected cases is calculated. Maximum likelihood estimation is used to define
clusters, and Monte Carlo hypothesis testing is used to determine the statistical significance of each
cluster39. Spatial scan statistics have been used widely in the context of malaria with the goal of
identifying areas to target for malaria control efforts in high and low transmission settings with data
collected in surveys and through routine surveillance40–44.
B.D. Ripley’s K(r) function is another method used to assess spatial heterogeneity in epidemiology. The
null hypothesis of the K function is a random labeling assumption, that the assignment of cases and
controls are distributed randomly given unit location45. K(r) estimates the frequency of an event relative
to the distance of other events in the area of interest46. Deviation from complete spatial randomness is
determined by examining a plot of the K function by distance r and comparing it to a random Poisson
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point process, or πr2. If there was a tendency for events to cluster in an area, the K function would be
higher than the πr2 curve, indicating that there would be more events than expected under the assumption
of complete spatial randomness. If there was a tendency for dispersion at a certain location, the plot of the
K function line would be lower than the πr2 curve. Though less frequently than spatial scan statistics, the
K function has also been used to assess spatial distribution of malaria to spatially target or assess malaria
interventions in high and low transmission settings in Africa and Asia47–51.
Global and local methods to answer the question “how similar are neighbors to one another?” include
Moran’s I and the Local Indicator of Spatial Autocorrelation (LISA). These methods of detection of
spatial autocorrelation can provide information to further investigate other similarities between defined
geographic areas or neighborhoods that are similar to or different from one another52. While this method
more difficult to interpret using spatial point data, it has been used to identify hot spots and cold spots of
malaria44,53,54. Other methods of assessing spatial clustering of malaria have been used, including several
Bayesian geostatistical modeling techniques55–58.

The use of spatial methods in malaria epidemiology
In lower transmission settings, researchers have used spatial methods to identify spatially dependent
drivers of persistent infection in a community41. Findings from these settings often do help identify
straightforward predictors of malaria positivity such as distance from a river or other type of vector
breeding site that may be targeted with a vector control activity such as indoor residual spraying targeting
those households35,42. In medium to high transmission settings, results of spatial analyses have varied, but
have generally been on a larger scale, examining either an urban area or using spatial data to look at
spatial distribution of malaria nationwide. One study in Mozambique found spatial heterogeneity of
malaria in the study area that did not change based on season, and higher transmission persisted in areas
close to a swampy area59. A study in Kampala, Uganda had similar results when examining an urban
cohort of children where risk of malaria infection was associated with distance from a swamp43. Studies in
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Malawi and Mali used household survey data to predict nationwide malaria prevalence, describing spatial
heterogeneity at a large scale; authors suggested that their findings could be used to guide strategies to
stratify interventions based on malaria burden56,58.

While there have been several analyses of malaria spatial data throughout Africa, evidence regarding
spatial distribution of malaria in high-transmission settings in southern Africa, including Mozambique
and even more so, from the highest transmission regions, is limited57,59–62. Additionally, the foremost
methodology for understanding malaria burden has been through periodic nationwide household surveys
that measure parasitemia often at a regional level63. The sampling methodology of most of these national
surveys do not allow for the assessment of spatial heterogeneity beyond the region or province, which
limits the ability to reliably use methods to examine hotspots or explore the feasibility of targeting
interventions at a health zone, village, or even neighborhood level, especially in lesser-populated rural
areas. The implementation of more focused household surveys that target a region or district level and
collect spatial point data may provide opportunities to apply spatial analysis techniques that examine
spatial point processes.
The use of serological tools to examine exposure to several tropical infectious diseases
Specimens collected in household surveys have generally targeted one disease to understand prevalence
along with questions about predictors of those specific diseases64. Examples include malaria indicator
surveys that measure malaria prevalence with microscopy or RDT63 and AIDS indicator surveys
measuring HIV prevalence65. Neglected tropical disease surveillance is typically based on the collection
of blood spots, eye swabs, urine, or stool samples in periodic surveys66. These surveys and specimen
collection can be resource intensive and require multiple specimens to be collected from the same
populations67.
Availability of multiplexing technology for surveillance allow for more efficient data collection,
minimize the number of biological specimens taken from participants in surveys and research studies, and
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allow public health practitioners to look beyond the disease-specific descriptive epidemiology and
interventions67,68. Additionally, within a disease, different serological markers may be used to deepen the
epidemiologic understanding of one disease. For example for malaria, antibody response for different
antigens will vary in duration and by number of infections69.
Luminex-bead antibody assays allow for the analysis of antibody responses to several antigens at once
from a single dried blood spot collected on filter paper with consistently high sensitivity and
specificity68,70. Sample analysis using this technology has been integrated into household surveys and
have provided valuable information about antibody prevalence of diseases of public health importance in
several countries70–73.
While multiplex assays have been used for sample analysis, increasing efficiency in data collection and
sample processing, often the statistical analysis is limited to just one pathogen or group of pathogens such
as vaccine preventable diseases, malaria, or NTDs to describe the distribution of seropositivity or assess
the effectiveness of an intervention5,72,74–77. Literature including information about several diseases has
generally been limited to seropositivity prevalence estimates70–73 and few have integrated survey data with
those results to examine common risk or protective factors78. Integrating survey with biomarker data
provides an opportunity to not only implement integrated disease surveillance and could provide evidence
about situations and behaviors that can inform the effectiveness of integrated disease control programs.
Antimalarial resistance
WHO recommends the implementation of therapeutic efficacy studies (TES) at least every two years in
malaria endemic countries to quickly identify reduced sensitivity to artemisinin-based combination
therapies used for the treatment of uncomplicated malaria79. Early identification of waning efficacy of a
drug may inform national malaria control program policy for malaria treatment.
During TES, patients are enrolled and followed for a defined period, during which they are monitored for
early treatment failures, late recurrence, or adequate clinical and parasitological response (ACPR)80. The
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primary results of a TES include uncorrected and PCR-corrected cumulative efficacy and per-protocol
efficacy. In malaria endemic settings in which TES are implemented, patients enrolled in the study may
become infected with a new parasite over the study period. To generate PCR-corrected estimates,
distinguishing new infections from recrudescent infections that indicate possible failure of the drug is
critical, especially in high transmission settings where individuals are likely to be reinfected. There are
molecular correction techniques available, and it is important to account for areas of high malaria
transmission where it is also likely for individuals to have multiple malaria infections at once81. There is
evidence that classic molecular correction techniques, such as comparisons of the genes for the merozoite
surface proteins (msp) 1, 2, and glutamate-rich protein (glurp)80, may be subject to amplification bias and
suppressing fragments in the case of multiple infections, increasing the likelihood to misclassify recurrent
parasitemia as reinfections, leading to overestimations of efficacy82,83.
Another method used for molecular correction includes the use of seven neutral microsatellite markers,
for which fragment lengths of neutral loci are measured and compared between day 0 and day of recurrent
parasitemia84. A Bayesian algorithm for comparison of the two samples that accounts for the baseline
prevalence of fragment lengths was developed that assigns each late recurrence a probability of
recrudescence, which can be used to calculate the final PCR-corrected efficacy estimates85. There is
evidence that this approach provides unbiased classification in all transmission settings, and a simulation
study has shown that this may especially useful in areas of higher transmission to prevent
misclassification bias82.
In addition to monitoring ACT efficacy, therapeutic efficacy studies may monitor molecular markers of
antimalarial resistance among Plasmodium falciparum parasites. Specific polymorphisms in the propeller
domain of the pfkelch13 (pfk13) gene86 have been associated with artemisinin resistance, a finding
described in Southeast Asia87 and recently in Rwanda, the first sub-Saharan African county with
published evidence of pfk13 mutation association with susceptibility to artemisinin88. Decreased
susceptibility to lumefantrine and amodiaquine has been associated with polymorphisms in the gene
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pfmdr1 and decreased susceptibility to amodiaquine has been associated with polymorphisms in the gene
pfcrt89.
Recent TES completed in DRC have demonstrated that the three ACTs used to treat uncomplicated
malaria in the public and private sector, artemether lumefantrine (AL), artesunate-amodiaquine (ASAQ),
and dihydroartemisinin piperaquine (DP) are efficacious in DRC, with per-protocol PCR-corrected
efficacies of over 90% in studies conducted between 2015–20174,90,91.
The results of an updated TES in DRC is needed to provide data to the DRC NMCP to make decisions
about treatment for uncomplicated malaria as recommended by WHO. As a country representing a large
portion of malaria cases on the continent, threats to ACT efficacy in DRC are especially important.
Furthermore, while the Bayesian statistical algorithm has been validated for higher transmission settings,
it has not been validated on the highest transmission settings found in areas like DRC. Further evidence
that may be used to prevent misclassification bias in molecular correction can ensure that accurate
estimates of therapeutic efficacy are used by decision-makers.
Statement of purpose
The purpose of this dissertation is to describe the epidemiology of malaria and co-endemic diseases of
public health importance in Mozambique and evaluate the efficacy of three ACTs in DRC, which
represent a malaria intervention critical for the reduction of disease in high transmission settings in subSaharan Africa.
In 2014, a survey was conducted in the Nampula province of Mozambique to assess the impact of a
universal long-lasting insecticide treated net (LLIN) campaign completed the year prior. Antibody
responses to 39 antigens representing malaria, diarrheal, respiratory, neglected tropical diseases, and
vaccine preventable diseases were measured using a multiplex bead assay, and a malaria RDT was
performed on all consenting survey participants. The first two studies will analyze data collected during
this survey. The third study will analyze data collected in five sites in DRC for therapeutic efficacy
monitoring.
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The first study will describe the spatial epidemiology of malaria in two high-burden districts in northern
Mozambique to explore the utility of exploration of local spatial heterogeneity in high-transmission
settings in targeting interventions. Understanding the spatial epidemiology of malaria using methods that
are practical and interpretable will contribute to WHO strategy and of stratifying and tailoring
interventions according to malaria burden92 in addition to addressing the evidence of meaningful variation
of malaria endemicity at local levels93. Furthermore, applying spatial analysis techniques to areas of high
transmission settings will fill a gap in the literature of describing spatial variation beyond a regional or
national level, and provide baseline information to progress overtime, with the ultimate goal of spatially
targeting persistent reservoirs of transmission.
The objective of the second paper is to investigate patterns in comorbidities for infectious diseases in
Nampula Mozambique. The understanding of multiple exposures present in the population of interest can
allow for more comprehensive understanding of the important causes of morbidity and mortality and to
monitor the success of programs such as mass drug administration for trachoma or routine immunization
programs71,94,95. Having the ability to examine evidence of exposure to multiple pathogens in tandem
could provide an understanding of the epidemiology of endemic diseases, which may support the clinical
management of illness for which there is no easy diagnosis at the peripheral levels of the health system
and be used to improve upon integrated disease prevention and treatment programs. This study will fill
the gaps in the literature of going beyond describing prevalence of seropositivity to multiple diseases or
focusing on one or a group of pathogens, and examine shared patterns, risk factors, and protective factors
between 40 diseases of public health importance in Mozambique.
The goal the third paper is to describe the results of a study examining the therapeutic efficacy of three
ACTs used for the treatment of uncomplicated Plasmodium falciparum malaria in five sites in DRC and
present the prevalence of molecular markers of resistance to artemisinin derivatives and partner drugs.
Current information about the efficacy of ACTs in DRC will support decisions about the national malaria
treatment guidelines in DRC. Ensuring that the ACTs used in a high-burden country such as DRC will
19 of 107

LF Moriarty
prevent excess morbidity and mortality due to ineffective drugs. Additionally, understanding the
prevalence of molecular markers of resistance in a large country may provide early warning of any drug
resistance issues for the continent.
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Abstract
Background
Mozambique has one of the highest malaria burdens in the world. Nampula province of Mozambique had
an estimated 66% malaria prevalence as measured by RDT in 2015, second only to Zambézia, which had
an estimated prevalence of 68%. As a “high burden high impact” country defined by the World Health
Organization, there an emphasis on using tools such as spatial analysis methods to tailor interventions at
more granular level to eliminate persistent reservoirs of transmission.
Methods
A household survey was conducted in 2014 in two districts in Mozambique’s Nampula Province:
Mecubúri and Nacala-a-Velha. A two-staged cluster sampling technique was used to select houses and a
questionnaire was administered to all consenting individuals present at the visit and included questions
regarding malaria knowledge and preventive behaviors, demographic, and socioeconomic indicators. A P.
falciparum malaria rapid diagnostic test was also administered as a measure of active or recent malaria
infection. To investigate spatial heterogeneity of acute malaria infection, three methods were used, the
Moran’s I statistic, B.D. Ripley’s K function, and spatial scan statistics.
Results
The Moran’s I test of global spatial autocorrelation provided evidence of clustering of households with
similar proportions of household members at short distances. Another test of global spatial clustering, the
K statistic demonstrated no evidence of difference in spatial autocorrelation between households with
malaria cases versus households without cases. Local clustering analysis found eight statistically
significant malaria clusters. The SatScan analysis malaria RDT positivity among children under five years
old revealed evidence of five cold spots, one of which was statistically significant and two hotspots, none
of which were statistically significant.
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Conclusions
While there was some evidence of clustering of cases or non-cases in a few instances, overall, the spatial
distribution of malaria infection across the study area was homogeneous. The results of this analysis show
that stratification at levels lower than a district level in regions of high malaria burden may not be
warranted.
Keywords: Malaria, P. falciparum, spatial analysis, Mozambique, household survey
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Background
Mozambique has one of the highest malaria burdens in the world, representing four percent of the world’s
cases and four percent of malaria deaths in 2018(1). Deaths attributed to malaria represent 42 percent of
all deaths among children under five years old, and 27 percent of deaths of people of all ages(2). Malaria
burden in Mozambique is heterogenous, with regional parasitemia estimates measured by rapid diagnostic
test (RDT) ranging from two percent in the capital of Maputo to 66 and 68 percent in the northern
provinces of Nampula and Zambézia, respectively(3).
The strategy for malaria control, led by the national malaria control program (NMCP) in Mozambique
includes providing access to vector control interventions such as insecticide-treated nets and Indoor
Residual Spraying , and ensuring that malaria cases are confirmed using a parasitological test and treating
positive tests with an appropriate antimalarial at the facility and community levels. Targeting preventive
and care seeking behaviors with social behavior change (SBC) activities and strengthening surveillance
and program management at all levels of the health system are also included(2).
The World Health Organization (WHO)’s Global Technical Strategy for Malaria 2016-2030(4) calls for
the reduction of malaria incidence by 90% by 2030. This ambitious goal will require the use of data,
including data collected in household surveys to track progress in addition to understanding the
epidemiology of malaria at increasingly smaller spatial scales to precisely target interventions. The WHO
strategy includes a special focus on driving down burden in highly endemic areas such as northern
Mozambique(5).
The method of malaria transmission is associated with location, increasing the likelihood of a spatially
nonrandom distribution of the malaria. Spatially nonrandom predictors include Anopheles breeding sites
and their proximity to houses, housing materials and type, occupation as well as environmental variables
including rainfall and altitude(6–10). There are several methods available to detect and quantify spatial
autocorrelation and used to describe malaria epidemiology with differing assumptions, methods, and data
availability.

28 of 107

LF Moriarty
Much of the information, including spatial data about malaria burden and its predictors come from
household survey data, which are not usually powered to make precise estimates of spatial clustering that
regional count data representative of an area of interest such as census or surveillance data may have the
power to do(11,12). Methods to assess spatial point patterns with survey data include assessment of
global spatial autocorrelation with methods such as Moran’s I and the K function to determine the
tendency of a variable of interest to cluster spatially, and local cluster identification techniques such as the
local indicator of spatial autocorrelation and spatial scan statistics(11). These methods provide different
outputs that may be triangulated to make inferences about disease patterns and spatially nonrandom
drivers of those patterns in the absence of population-wide spatial data.
Spatial methods have been widely used in the context of malaria in low to moderate transmission areas
that are candidates for malaria elimination to identify reservoirs of infection that are driving most of the
transmission in an otherwise low transmission area(9,10,13–16), but the use of these methods in high
transmission areas to identify areas with higher or lower than average prevalence has been limited or used
to describe or model malaria distribution at a national-scale(17–20).
Understanding the spatial epidemiology of malaria in high transmission areas using methods that are
practical and interpretable will contribute to WHO strategy of stratifying and tailoring interventions
according to malaria burden at a more granular level(14). The goal of this analysis is to utilize methods
practical for programmatic use to describe local spatial patterns of malaria in a high transmission setting
to identify opportunities to target control activities at a local level.
Methods
Data collection
A household survey was conducted in 2014 in two districts in Mozambique’s Nampula Province:
Mecubúri and Nacala-a-Velha. Detailed methods of the data collection processes are described
elsewhere(21). Briefly, A two-staged cluster sampling method was used to randomly select 20 clusters in
each district and 16 houses within each cluster in 2013 prior to a mass bed net distribution campaign. The
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2014 survey targeted the households that were included in the prior year’s survey. Every individual
present in the household was invited to participate in a questionnaire that included indicators of household
and individual socioeconomic and behavioral factors for which there is evidence of association with
malaria. All respondents were asked to be administered a P. falciparum HRP2-specific RDT (SD Bioline,
Yongin, Republic of Korea). Those who tested positive were treated according to the national case
management guidelines(22). The longitude and latitude of each household was recorded by the survey
enumerator using an electronic data collection tool. RDT result was used as a measure of current or recent
parasitemia and as the main outcome variable in the analysis. Techniques to identify clusters and patterns
of clustering were used to describe the spatial distribution in the study population. Only the 2014 results
are included in the present analysis.
Moran’s I
The Moran’s I statistic measures spatial autocorrelation of a spatial variable with variation in that variable
by neighboring areas. Global Moran’s I can be used to evaluate evidence of influence of space on a
variable of interest(23). A positive value for Moran’s I indicates evidence of spatial clustering, or a
tendency for observations to have values similar to their neighbors. A negative value indicates that
observations tend to have values dissimilar to their neighbors. Values of 0 indicate no evidence of spatial
autocorrelation. The null hypothesis under the Moran’s I test of spatial association is that that values of
the variable of interest are randomly distributed. In its basic form the Moran’s I statistic calculation is
below where i and j are two locations or observations; zi is the difference between the observation and its
mean. Spatial weights are denoted by wi,j for features i and j, S is the sum of all spatial weights, and n is
the total number of observations. Statistical significance is evaluated for the index through a z-score and a
p-value. If there is evidence of clustering in an area, I will be positive, and if dispersed, negative, if close
to zero, then there is evidence of random distribution of that spatial attribute(11).
𝑛𝑛 ∑𝑛𝑛𝑖𝑖=1 ∑𝑛𝑛𝑗𝑗=1 𝑤𝑤𝑖𝑖𝑖𝑖 𝑧𝑧𝑖𝑖 𝑧𝑧𝑗𝑗
𝐼𝐼 =
∑𝑛𝑛𝑖𝑖=1 𝑧𝑧𝑖𝑖2
𝑆𝑆0
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Global Moran’s I analysis was used to evaluate clustering based on proportion of household RDT
positivity in the study area. Households for which there are no RDT results were not included in the
analysis. Moran’s I statistics for proportion of household members testing positive by RDT were
calculated at 10 distances classes from the latitude and longitude of each house up to two kilometers.
Statistical significance was defined as p<0.05.
The Local Indicator of Spatial Autocorrelation (LISA), based on the Moran’s I statistic, is a measure of
spatial autocorrelation that allows for analysis at the observation-level. The global Moran’s I statistic is
simply the sum of the LISA values for all observations. A single LISA statistic provides information
about the extent to which the value of one observation is similar to its neighbors(23).
To investigate local clusters, weights were calculated based in Euclidian distance between households.
Local Moran’s I statistics were calculated for each household. Statistically significant (p<0.05) clusters of
households were defined as high proportion of RDT positivity with high neighbors, low near low
neighbors, low near high neighbors, and high near low neighbors.
K Function
B.D. Ripley’s K(r) function was used to determine the spatial dependence of RDT status in the study
area(24). The null hypothesis of the K function is a random labeling assumption, that the assignment of
cases and controls are distributed randomly given unit location(25). K(r) estimates the frequency of an
event relative to the distance of other events in the area of interest and is described below; λ is the
intensity of events in the study area(24).

𝐾𝐾(𝑟𝑟) =

𝐸𝐸[𝑛𝑛 𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 𝑤𝑤𝑤𝑤𝑤𝑤ℎ𝑖𝑖𝑖𝑖 𝑟𝑟 𝑜𝑜𝑜𝑜 𝑎𝑎 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 𝑐𝑐ℎ𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜 𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒]
𝜆𝜆

Deviation from complete spatial randomness is determined by examining a plot of the K function by
distance r and comparing it to a random Poisson point process, or πr2. If there was a tendency for events
to cluster in an area, the K function would be higher than the πr2 curve, indicating that there would be
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more events than expected under the assumption of complete spatial randomness. If there was a tendency
for dispersion at a certain location, the plot of the K function line would be lower than the πr2 curve. The
random labeling assumption can be tested by examining the difference in K functions between two
groups, in this case, RDT positive cases, and RDT negatives, or controls. If the difference in K functions
is zero, one may conclude that there is no meaningful difference in distribution of cases and controls in
the study area, or that there is no relationship between malaria RDT positivity and space. Significance
testing of the K function can be calculated through a Monte Carlo test, comparing the observed point
labels to independent N random permutations of the outcomes(26).
Households with at least one positive RDT were defined as case households, and households with no
RDT positives were defined as controls. The difference in the K function estimates of cases and controls
was plotted and compared with zero to test the hypothesis that cases and controls are randomly distributed
by distance r. Isotropic edge correction was used to estimate K(r) to account for observations near the
border of the study area(11). Monte Carlo simulations (n=999) were used to construct bands around the
expected value under the assumption of complete spatial randomness(26).
Spatial scan statistic
A common method used to identify clusters of malaria or other infectious diseases in a given area is the
use of Kulldorff’s spatial scan statistic(27–34). This method uses geographic point data to detect whether
the outcome of interest is distributed randomly over space and detects clusters and assigns statistical
significance to them. To detect clusters, an area is scanned gradually with a predefined circular window
size, representing potential clusters. At each scanning window, the number of observed and expected
cases is calculated and tested using a likelihood ratio test, with expected number of cases representing
random distribution of cases and controls across households. Monte Carlo hypothesis testing generating a
permutations of observed labeling of cases across the study area is used to determine the statistical
significance of each cluster(35).
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For this analysis, a scanning window of 10% of the population was used with the Bernoulli model to
compare cases to non-cases at each household. To calculate statistical significance, 999 Monte Carlo
replications were used. A case was defined as a child under five years old in the dataset testing positive by
RDT, a negative was a child under five years old with a negative RDT. A significance level of P=.05 was
used to determine statistical significance(36).
SaTScanTM software (version 9.6) was used for the spatial scan cluster analysis. R version 3.5.2 (R
Foundation for Statistical Computing, Vienna Austria) was used for the remainder of analyses. R
packages ggplot2(37) and spatstat(38) were used to generate figures and perform the K function
analysis(38).
Results
Description of study sample
A total of 365 households and 1282 individuals were included in the analysis, 184 households and 704
individuals in Mecubúri and 181 households and 578 individuals in Nacala-a-Velha. There was an
average of 3.5 persons reported in each household. Nineteen percent of the study sample was composed
of children under five years old.
Among persons included in the analysis, 782 (61%) tested positive for malaria by RDT, 498/704 (71%) in
Mecubúri, and 284/578 (49%) in Nacala-a-Velha. Among children under five, 209 (78%) tested positive
for malaria by RDT, 129/146 (88%) in Mecubúri and 90/123 (65%) in Nacala-a-Velha. The mean
proportion of household members testing positive by RDT in the study sample was 53% (standard
deviation 39%).
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Figure 1.1: Location of households included in sample and malaria rapid diagnostic test (RDT)
results in Mecúburi and Nacala-a-Velha, Nampula Province, Mozambique

Table 1.1: Summary of study sample of malaria RDT positivity in two districts in Nampula
Province, Mozambique, 2014

Mecubúri
Nacala-a-Velha
Total
a

Households

Individualsa

184
181
365

704
578
1282

All ages
Positive RDT
(%)
498 (71)
284 (49)
782 (61)

Under five years old
Individualsa
Positive RDT
(%)
146
129 (88)
123
80 (65)
269
209 (78)

excluding individuals with no RDT result

Moran’s I & Local Moran’s I
All households for which RDT results were available (n=365) were included in the calculation of the
Moran’s I statistic. Moran’s I was calculated over 10 distance classes from 0 to 2 kilometers. The distance
classes of 0.1 km (coefficient: 0.06, p<0.01), 0.3 km (coefficient: 0.048, p<0.01). and 0.5km (coefficient:
0.048, p=0.01) yielded statistically significant clustering with values of above 0, indicating a pattern of
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households to be similar to their neighbors with respect to proportion of RDT-positive persons in their
households when the neighbors are less than one half of a kilometer apart (Figure 2).
The local analysis yielded eight instances (two percent of households) of local spatial autocorrelation;
three (0.8%) where a household had a relatively high prevalence relative to its neighbors, three (0.8%)
where a household had a relatively low prevalence relative to its neighbors, and two (0.5%) where a
household and their neighbors all had lower than average prevalence.
Figure 1.2: Moran’s I statistic for global spatial autocorrelation of proportion of household
members testing positive for malaria by rapid diagnostic test over 10 distance classes in Nampula
Province, Mozambique, 2014

K Function
In Mecubúri, there were 148 (80%) case households with at least one person testing positive, and 36
(20%) control households where nobody tested positive. There was no evidence of a difference in K
functions of the cases versus control households at any distance (p= 0.68).
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In Nacala-a-Velha, there were 115 (64%) case households with at least one person testing positive, and 65
(35%) control households, with no person testing positive. There was no evidence of a difference in K
functions of the cases versus control households at any distance (p=0.75).
Figure 1.3: Difference in K Functions between households with at least one positive P. falciparum
malaria rapid diagnostic test and households with only negative P. falciparum rapid diagnostic tests
in two districts in Nampula Province, Mozambique

Spatial Scan statistics
The spatial scan analysis revealed two clusters of RDT negative households in Mecubúri with including
two households each, one of which was statistically significant (p=.00045). In Mecubúri, 2.9% of
households were identified within one of the identified cold spots. In Nacala-a-Vela, five clusters were
identified: two hotspots and three cold spots, none of which were statistically significant. The hotspots
included five and six households, and the cold spots included ten, nine, and two households. In Nacala-aVela, 9.7% of households were within a hotspot and 18.6% of households located within a cold spot.
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Figure 1.4: Results of hot and cold spot analysis using spatial scan statistics in Nacala-a-Velha and
Mecubúri, Nampula, Mozambique.
Dots indicate households included in the survey sample for which RDT results were available for children
under five years old. Circles indicate hot or cold spots of RDT positivity. Blue denotes cold spots, and red
denotes hotspots.

Table 1.2: Hotspots and coldspots of P. falciparum rapid diagnostic test identified using spatial scan
statistics in two districts of Nampula province, Mozambique, 2014
Number of
households
# RDT
Cluster
(individuals)
positive (%)
Observed/expected
P-value
Mecubúri
Coldspot 1
2 (7)
1(14)
0.16
.00045a
Coldspot 2
2(3)
1(33)
0.38
0.9165
Nacala-aColdspot 3
8 (8)
1 (13)
0.19
0.1703
Velha
Coldspot 4
10 (10)
2 (20)
0.31
0.2500
Coldspot 5
2 (3)
0 (0)
0
0.8975
Hotspot 1
6 (6)
6 (100)
1.54
0.9755
Hotspot 2
4 (5)
5 (100)
1.54
0.9959
a
Statistically significant
Discussion
The Moran’s I test of global spatial autocorrelation provided evidence of clustering of households with
similar proportions of household members at short distances. Another test of global spatial clustering, the
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K statistic demonstrated no evidence of difference in spatial autocorrelation between households with
malaria cases versus households without cases.
Local clustering analysis yielded a handful of statistically significant instances of local spatial
autocorrelation. The SatScan analysis malaria RDT positivity among children under five years old
revealed evidence of five cold spots, one of which was statistically significant and two hotspots, none of
which were statistically significant.
This analysis shows that malaria prevalence in this district as measured by RDT, which is evidence of
active or recent infection(39) is extremely high and homogenous among young children at the districtlevel, indicating widespread high transmission intensity(40). The difference in malaria prevalence
between the two districts shows that even in a very high-burden region, it might be worth exploring the
between-district heterogeneity and predictive factors of these differences including ecological such as
differences in rainfall or altitude, environmental such as access to care or other preventive or curative
services, and cultural or normative differences that may affect preventive or care seeking behaviors.
This analysis included the use of three methods that required the use of three different ways of measuring
the outcome variable. The Moran’s I and LISA statistics used proportion of RDT positivity at the
household level; The K function used a binary outcome at the household level (at least one positive case
in a household); The spatial scan statistic used individual-level data for each location. The common thread
across the methods was the use of RDT positivity as a measure of current or recent infection. The
variability of these three measurements allows for triangulation of the spatial distribution of malaria
infection in the study area, and all yielded consistent findings of spatial homogeneity of malaria infection
in this sample.
Intervention stratification should be informed by data regarding the epidemiologic setting and spatial
distribution of malaria and its predictors. At very low transmission settings, there could be reason to tailor
interventions to the very local level, especially when implementing resource-demanding programs such as
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reactive case detection and treatment(41). While a handful of anomalous groupings of households were
identified in this analysis, there was no obvious clustering pattern identified using any of the methods in
this analysis. This confirms that in high-burden settings, the focus of ensuring strong coverage of malaria
control measures including universal ITN coverage, access to case management, IPTp and behavioral
interventions to drive down transmission should be the priority. Strong surveillance to track progress and
identify areas that remain drivers of transmission as incidence declines is also critical. Any tailoring of
interventions in the context of limited resources such as targeting indoor residual spraying may be
considered at the district level.
Limitations
While helpful in an exploratory analysis, the survey and sampling methodologies were not originally
designed for precise spatial analyses, therefore the number and distribution of observations may not have
been sufficient to make meaningful conclusions about the spatial clustering patterns. Additionally, this
analysis did not include information about covariates, especially spatially heterogeneous predictors that
may drive hotspots. Finally, while monospecies RDTs have been deemed appropriate for use in
Mozambique(42), there are still limitations to their use to determine the prevalence of malaria in a given
area, given their limits of detection in the case of low parasite density which can be a common occurrence
in areas of high endemicity(43). Additionally, the use of a P. falciparum-only test does not capture
additional malaria species that may be circulating.
Conclusions
Further exploration of the spatial distribution between districts may help inform strategy for intervention
stratification in high transmission settings. In a high transmission setting, it may be more useful to
examine temporal variation in the spatial distribution of malaria by conducting longitudinal studies.
Understanding the areas that may be serving as reservoirs of transmission in a period of relatively lower
transmission may be useful in spatial targeting of interventions in high-transmission areas(14). Finally,
spatially representative sampling and collection of more spatially dependent covariates, or the use of
routine surveillance data would add to the precision and validity of future spatial analyses(44).
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This exploratory analysis of spatial distribution within two high-burden districts of Mozambique
presented evidence of within-district spatial homogeneity of malaria. When considering tailoring malaria
interventions to the epidemiology of a certain area, malaria control programs may consider tailoring to the
district level at the lowest in high burden settings.
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Abstract
Communicable, maternal, neonatal and nutritional diseases have remained the most common cause of
disability and death in Mozambique and surveillance for infectious diseases has typically been pathogen
specific. The availability of multiplex platforms for the assessment of antibody responses to antigens of
interest allows for the collection of information about several antigens of interest in a single specimen. In
2014, a household survey was undertaken in Nampula Province of Mozambique. A questionnaire was
administered to selected households and dried blood spots were collected for all consenting household
members. Multiplex analysis was used to measure antibody responses to 39 antigens representing
infectious diseases of public health importance. The survey data were used to calculate adjusted log-MFI
values for each antigen. A comparison matrix to compare adjusted log-MFI values was developed using
the Pearson correlation coefficient for each pairwise comparison. Data representing 1,156 participants
were included in the analysis. Of 702 pairwise comparisons of adjusted log-MFI values, 684 (97%) were
statistically significant, 460 (67%) of which had positive correlations, and 224 (33%) were negatively
correlated. Age, sex, and district were the most common predictors of log-MFI. Multiplex assays coupled
with cross-sectional survey data regarding practices, socioeconomic indicators, and access and use of
healthcare services can provide insights about common predictors that may be associated with exposure to
multiple pathogens. By understanding the epidemiology of several pathogens and their common
predictors, public health practitioners can target common risks of exposure to diseases making more
efficient and effective public health interventions in resource-limited settings.
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Introduction
Communicable, maternal, neonatal and nutritional diseases have remained the most common cause of
disability and death in Mozambique. Under 5 mortality was an estimated 73.8 per 1,000 live births as of
2017, making Mozambique among the countries with the highest rates of child mortality in the world1.
Malaria is a substantial contributor to morbidity and mortality in Mozambique and is responsible for 29
percent of all deaths and 42 percent of deaths among children under 5 years old, with the highest burden
in the provinces of Zambézia and Nampula2. In 2017 in Mozambique, malaria was the third most
common cause of death in all ages following HIV/AIDS and neonatal disorders3. While nationwide
administrative childhood vaccination coverage reported to be high, there is evidence that only 65.8% of
children received all eight basic vaccinations in 20154,5. Neglected tropical diseases remain a significant
cause of disability throughout the country, including lymphatic filariasis, which shares a common vector
with malaria6,7. In a 2015 nationwide survey, 11% of children under 5 reported having diarrhea in
previous 2 weeks5; the most frequent causes of diarrhea in rural Mozambique include Rotavirus,
Cryptosporidium sp., Shigella sp., E. coli, and adenovirus8.
In 2010, the World Health Organization (WHO) recommended the universal use of diagnostic tests for
before treatment to avoid indiscriminate use of antimalarials and minimize resistance, reduce costs
associated with antimalarials, and improve treatment of persons with non-malaria fevers9. The
accessibility of point of care diagnostic tools for malaria clinical management allows for understanding its
epidemiology at granular levels of the health system through routine surveillance data in electronic
surveillance systems10. Surveillance for vaccine preventable diseases, respiratory infections, and diarrheal
diseases commonly relies on case-based surveillance or sentinel surveillance systems with strong
laboratory capacity 8,11,12. Neglected tropical disease surveillance is typically based on the collection of
blood spots, eye swabs, urine, or stool samples in periodic surveys13.
The availability of multiplex platforms for the assessment of antibody responses to antigens of interest
allows for the collection of information about several pathogens of interest in a single assay of eluate
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from a dried blood spot, the collection of which is simple compared to other types of samples. This
capability can allow for the understanding of multiple exposures present in the population of interest,
allowing for more comprehensive understanding of the important causes of morbidity and mortality and
to monitor the success of programs such as mass drug administration for trachoma or routine
immunization programs14–16. Having the ability to examine evidence of exposure to multiple pathogens in
tandem could provide an understanding of the epidemiology of endemic diseases, which may support the
clinical management of illness for which there is no easy diagnosis at the peripheral levels of the health
system and be used to improve upon integrated disease prevention and treatment programs. Moreover,
understanding the common predictors of exposure to different infectious pathogens may inform public
health programming that targets behaviors or circumstances that make some more vulnerable to multiple
illnesses than others.
In 2014, a survey was conducted in the Nampula province of Mozambique to assess the impact of a
universal long-lasting insecticide treated net (LLIN) campaign completed the year prior. Antibody
responses to 39 antigens representing malaria, diarrheal, respiratory, neglected tropical diseases, and
vaccine preventable diseases were measured using a multiplex bead assay. This objective of this analysis
is to investigate patterns in comorbidities for infectious diseases in Nampula Mozambique, a highly
endemic for malaria and other tropical diseases.
Methods
Description of study area
Nampula is a coastal province in the northeast of Mozambique and has one of the highest poverty rates in
the country, measured at 64.9% in 2014/201517. Nampula’s economy is largely based on agriculture and
the province is a large producer of cotton18. Among persons between 15 and 49 years old, the mean years
of education is an estimated 4.4 years among males and 3.39 years among females19.
In 2014, the under 5 mortality per 1,000 live births in Nampula province was estimated as 86.1, and the
mean diarrhea prevalence among children under 5 years old was an estimated 31 per 1,000. Prevalence of
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stunting among children under 5 was an estimated 0.43%. The coverage of the first dose of the diphtheriapertussis-tetanus vaccine was 93.2% and third dose was 84.9%. The estimated prevalence of P.
falciparum infection in 2014 in Nampula was 48% among all ages. Nampula, along with Zambézia
province have the highest prevalence of malaria among 11 provinces in Mozambique, and Nampula has
the highest prevalence of schistosomiasis. The prevalence of HIV among persons between 15 and 49
years old was an estimated 6.2% in 20155,19,20.
Survey
A household survey was conducted October-November in 2013 and 2014 in 2 districts in Mozambique’s
Nampula Province: Mecubúri and Nacala-a-Velha. A 2-staged cluster sampling method was used to
randomly select 20 clusters in each district, and 16 houses within each cluster were chosen in the first
survey. In the second survey, the same households were visited with no replacement households. Every
individual present in the household at the time of data collection was invited to participate in a
questionnaire that included indicators of household and individual socioeconomic and behavioral factors
for which there is evidence of association with malaria. Up to 6 10 mcL spots of capillary blood were
collected on filter paper (TropBio, Cellabs, Sydney, Australia) in addition to administration of a P.
falciparum HRP-2 specific rapid diagnostic test (SD Bioline, Yongin, Republic of Korea). If the RDT
was positive, participants were treated for malaria according to the national guidelines for malaria
treatment21. The present analysis only includes data from the second survey completed in 2014.
Laboratory analysis
Laboratory analysis was carried out in the malaria laboratory at the Centers for Disease Control and
Prevention (CDC) in Atlanta, GA, USA. Details of the laboratory analysis are previously described22.
Briefly, dried blood spots were diluted to a final dilution of 1:400 of serum and immunoglobulin G (IgG)
antibody response to 39 antigens plus one control antigen were analyzed using a multiplex bead
platform23. Antigens were coupled to Seromap (Luminex Corp., Austin, TX), or BioPlex COOH (BioRad,
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Hercules, CA) beads. Consistency was ensured by including a buffer-only blank and 6 control sera and by
duplicating runs. The 2 median fluorescence intensity (MFI) values minus the buffer-only blank value
were used to calculate the final average MFI minus background value (MFI-bg). Antigen responses were
repeated for samples for which there were discordant results between the 2 runs as defined by a
coefficient of variation of more than 15%14. Antigen descriptions and coupling descriptions are described
in Supplemental Table 2.1.
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Table 2.1: Antigens and corresponding infectious agents measured in Mozambique household
survey, 2014
Antigen

Infectious Agent

Malaria
Pvivax

Plasmodium vivax

Pfalcip

Plasmodium falciparum

Pmalar

Plasmodium malariae

Povale

Plasmodium ovale

PfCSP

Plasmodium falciparum

Pflsa1

Plasmodium falciparum

Non-malaria mosquito-borne
CHIKV

Chikungunya

Wb123

Lymphatic filariasis

Bm14

Lymphatic filariasis

Bm33

Lymphatic filariasis

VLP3

Dengue

RVFV

Rift Valley fever

Vaccine Preventable
MeaslesQ

Measles

Rubella

Rubella

Dip

Diphtheria

Tet

Tetanus

Diarrheal
Norwalk

Norovirus

Sydney

Norovirus

StCloud

Norovirus

VSP3

Giardia

VSP5

Giardia

SEA

Schistosomiasis

ETEC

Escherichia coli

Cholera

Cholera

SalB

Salmonella
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SalD

Salmonella

Campyp18

Campylobacter

Campyp39

Campylobacter

Other neglected tropical diseases
pgp3

Trachoma

CT694

Trachoma

YAWSrp17

Yaws

YawsTmpA

Yaws

T24H

Cysticercosis

SAG2

Toxoplasma

AscHb

Ascaris

NIE

Strongyloides

Cp17

Cryptosporidium

Cp23

Cryptosporidium

CpP2

Cryptosporidium

Statistical Analysis
Only participants for whom results from the multiplex analysis were generated were included in statistical
analyses. Density plots were generated for log-MFI values for all ages and by age category24. To generate
adjusted log-MFI values, linear regression models built using log-MFI values for each pathogen as the
outcome variable were built using forward and backward stepwise selection using the Akaike Information
Criterion25. The full model included items collected during the household survey including district,
cluster, mosquito net received during 2013 campaign, socioeconomic status category, malaria knowledge
index score, household size, bed net ownership, sex, relationship to the head of household, malaria RDT
result, age category, whether the sleeping space had a bed net, household distance from a health facility,
household income type, occupation of the head of household, highest level of schooling for the head of
household, number of sleeping spaces, and sufficient number of mosquito nets to cover sleeping spaces.
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The adjusted log-MFI using each pathogen’s regression model for each individual in the sample was
calculated. A comparison matrix to compare corrected log-MFI values was developed using the Pearson
correlation coefficient for each pairwise comparison. Statistical significance was defined at α=0.01.
Statistical analyses were carried out using R (R Foundation for Statistical Computing, Vienna Austria).
Ethical Considerations
The Mozambique National Bioethics Committee approved the study. Written consent was provided by
adult participants and on behalf of child participants. CDC staff provided technical assistance in data
collection and analysis and were considered to be non-engaged in this research by the Office of the
Associate Director for Science, Center for Global Health.
Results
Data representing 1,156 participants were included in the analysis. A total of 721 participants were
excluded due to missing data.
Table 2.2: Characteristics of sample of household survey conducted in 2 districts of Nampula
Mozambique, 2014
Mecubúri
N = 619

Nacala-a-Velha
N = 537

<5

126 (20%)

117 (22%)

5-10

137 (22%)

114 (21%)

10-14

56 (9.0%)

44 (8.2%)

14-20

54 (8.7%)

32 (6.0%)

20-30

87 (14%)

70 (13%)

30-40

76 (12%)

53 (9.9%)

40-90

83 (13%)

107 (20%)

Female

339 (55%)

289 (54%)

Male

280 (45%)

248 (46%)

Head

115 (19%)

122 (23%)

Spouse

119 (19%)

95 (18%)

Child

286 (46%)

232 (43%)

Other

99 (16%)

88 (16%)

Characteristic
Age (in years)

Sex

Relationship to head of household
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Malaria knowledge index score

0.24 (0.02, 0.43)

0.28 (0.13, 0.46)

Sleeping space has an ITN

296 (48%)

394 (73%)

Net received during campaign

330 (53%)

462 (86%)

Household size

5 (4, 7)

5 (4, 7)

1 - lowest

135 (22%)

94 (18%)

2

112 (18%)

61 (11%)

3

132 (21%)

99 (18%)

4

90 (15%)

137 (26%)

5 - highest

150 (24%)

146 (27%)

Less than 30 min on foot

161 (26%)

127 (24%)

1 to 2 hours on foot

159 (26%)

138 (26%)

30 min to 1 hour on foot

45 (7.3%)

50 (9.3%)

More than 2 hours on foot

254 (41%)

222 (41%)

Salaried

27 (4.4%)

78 (15%)

None

408 (66%)

255 (47%)

Do not know

4 (0.6%)

49 (9.1%)

Occasional

180 (29%)

155 (29%)

Farmer

544 (88%)

354 (66%)

Manual laborer

34 (5.5%)

96 (18%)

Other

5 (0.8%)

27 (5.0%)

Fisherman

0 (0%)

7 (1.3%)

Vendor

36 (5.8%)

53 (9.9%)

Primary 1

207 (33%)

251 (47%)

Primary 2

73 (12%)

43 (8.0%)

Middle

16 (2.6%)

21 (3.9%)

Secondary

40 (6.5%)

21 (3.9%)

None

276 (45%)

194 (36%)

Do not know

7 (1.1%)

7 (1.3%)

1

73 (12%)

42 (7.8%)

2

187 (30%)

200 (37%)

Household socioeconomic status index

Distance from closest health facility

Household income

Head of household occupation

Head of household school

Number of sleeping spaces in household
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3

249 (40%)

194 (36%)

4

67 (11%)

70 (13%)

5

20 (3.2%)

20 (3.7%)

6

21 (3.4%)

11 (2.0%)

7

2 (0.3%)

0 (0%)

Negative

188 (30%)

272 (51%)

Positive

431 (70%)

265 (49%)

174 (28%)

323 (60%)

Pf RDT result

At least one ITN per sleeping space
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Figure 2.1: Density plots of Log MFI values by antigen, Nampula Mozambique household survey,
2014
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Associations
Of 702 pairwise comparisons of adjusted log-MFI values, 684 (97%) were statistically significant, 460
(67%) of which had positive correlations, and 224 (33%) were negatively correlated. All adjusted logMFI values for antigens for mosquito-borne illnesses were positively correlated with one another.
Similarly, comparisons among all mosquito-borne illnesses, including all malaria markers were positive.
Among vaccine preventable diseases, measles was positively associated with rubella and diphtheria as
were rubella and diphtheria. Measles was negatively associated with tetanus. There was no evidence of
statistically significant association between tetanus and rubella and diphtheria.
Of the 3 norovirus serotypes, Norwalk and Sydney were statistically significantly negatively associated
with each other, as were Sydney and St. Cloud. Norwalk and St. Cloud were positively associated with
one another. The 2 types of Giardia intestinalis antigens (VSP3 & VSP5) were positively associated, as
were the 2 types of Salmonella sp. lipopolysaccharides (LPS B & LPS D) and 2 Campylobacte jejuni
antigens (p18 & p39). There were no other apparent positive or negative trends among the diarrheal
diseases as a group. Nearly all pairwise comparisons between neglected tropical diseases were positive.
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Figure 2.2: Matrix of Pearson correlation coefficients and p-values of adjusted log-MFI for 40
antigens measured using a multiplex bead assay, Nampula, Mozambique, 2014

Blue denotes positive correlation
Red denotes negative correlation
Shade denotes strength of correlation
Numbers in boxes denote p-values, 0 denotes p-value of <0.01
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Predictors
Age was the strongest predictor of seropositivity and included in the majority (97%) of the models and
increased age was more likely to be associated with increased log-MFI than decreased.
Sex was included in over half of the models (54%), and district, relationship to head of household,
socioeconomic status, and distance from health facility were included in between 38 and 44% of the
models. Presence of a net on the sleeping space was a predictor included in the fewest models (18%).
Higher scores on the malaria knowledge index was associated with decreased odds of seropositivity for 4
non-malaria antigens and 3 malaria antigens. Receipt of an LLIN during the recent universal coverage
campaign was associated with decreased log-MFI values for 7 non-malaria antigens and 3 malaria
antigens (P. ovale).
Table 2.3: Variables included in linear regression models regressing covariates on log-MFI for 39
antigens, Nampula, Mozambique, 2014
Variable

Number of models
included (%)

Risk factor (%)

Protective (%)

30 (79)
29 (76)
29 (76)
30 (79)
30 (79)
30 (79)

8 (21)
9 (24)
9 (24)
8 (21)
8 (21)
8 (21)

6 (38)
8 (50)
9 (56)

10 (62)
8 (50)
7 (44)

10 (59)
10 (59)
12 (71)
9 (53)

7 (41)
7 (41)
5 (29)
8 (47)

5 (33)
6 (40)
6 (40)

10 (66)
9 (60)
9 (60)

5 (42)
4 (33)
7 (58)

7 (58)
8 (66)
5 (42)

4 (27)
6 (40)
3 (20)
0 (0)

11 (73)
9 (60)
12 (80)
15 (100)

Age in years (ref: <5)
5-10
10-14
14-20
20-30
30-40
40-90
Relationship to head of household (ref: head)
spouse
child
other
Household socioeconomic status index (ref: 1)
2
3
4
5
Distance from closest health facility (ref: less
than 30 min on foot)
30 min to 1 hour on foot
1 to 2 hours on foot
More than 2 hours on foot
Household income (ref: salaried)
do not know
none
occasional
Head of household occupation (ref: farmer)
manual laborer
fisherman
vendor
other

38 (97)

16 (41)

17 (44)

15 (38)

12 (31)

15 (38)
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Head of household school (ref: primary 1)
primary 2
middle
secondary
do not know
None
Number of sleeping spaces in household
Result of Pf RDT
At least one ITN per sleeping space
Village
District Nacala-a-Velha
Sex male
Malaria knowledge index score
Sleeping space has a net
Net use index
Received an ITN during campaign
Household size

10 (26)

10 (26)
15 (38)
20 (51)
21 (54)
16 (41)
21 (54)
12 (31)
7 (18)
9 (23)
13 (33)
11 (28)

8 (80)
2 (20)
5 (50)
8 (80)
5 (50)
3 (30)
12 (80)
17 (85)
NA
3 (19)
1 (5)
5 (42)
3 (43)
7 (78)
3 (23)
7 (64)

2 (20)
8 (80)
5 (50)
2 (20)
5 (50)
7 (70)
3 (20)
3 (15)
NA
13 (81)
20 (95)
7 (58)
4 (57)
2 (82)
10 (77)
4 (36)

Discussion
This analysis examined the tendency for immune status to 39 antigens representing pathogens endemic to
the Nampula province of Mozambique to share common predictors defined by individual and household
level variables collected during a household survey. Age was the strongest predictor of serostatus,
followed by sex and district.
Many associations between pathogens were expected based on common route of transmission,
particularly the mosquito-borne diseases such as malaria, lymphatic filariasis and dengue. P. vivax did not
follow this pattern but was likely because there were very few individuals in the sample who had higher
MFI-values indicating seropositivity for P. vivax, reducing the ability to identify strong predictors.
Among the vaccine preventable diseases, measles, rubella, and diphtheria shared common predictors,
which may be an indication of comprehensive EPI coverage among those with any EPI coverage (i.e.
those with evidence of antibody response to one are more likely to have evidence of antibody response to
all 3). The negative or null association of these 3 antigens with tetanus may be an indication of weaker
coverage of tetanus boosters coverage, which are scheduled for first and second grades of school.
Additionally, male sex was associated with decreased log-MFI for tetanus, which may also be an
indication of effective booster coverage among women of reproductive age, confirming previous findings
from Mozambique and other countries26.
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The negative associations among the norovirus serotypes may be explained by outbreaks of different
serotypes occurring at different periods, as age was a predictor for all 3 serotypes. For example, older age
was associated with increased log-MFI values for the Norwalk and St. Cloud serotypes, but with
decreased log-MFI values for the Sydney serotype. It is possible there was a more recent outbreak among
young children for the Sydney serotype to which adults were less likely to be exposed27. This pattern is
congruent with evidence that predominant strains of norovirus emerge, replacing the previous
predominant strain with lack of evidence of cross-immunity between strains28.
Most antigens representing neglected tropical diseases were co-linear, which is logical given that many
share routes of transmission, many associated with water, sanitation and hygiene access and practices,
which were not measured directly in the survey questions, but other predictors such as SES may have
served as a proxy29.
Age was the most common predictor of antibody response and was included in the majority of the
prediction models. Age can be a predictor of disease exposure27, access to or use of prevention or
healthcare8, or waning immunity26 and varies by pathogen and antigen used to measure exposure. While
SES had predictive power in the prediction models, there was no clear pattern of higher or lower SES
being associated with higher adjusted MFI-values in any grouping of pathogens. Notably, higher scores
on the malaria knowledge index and LLIN use as protective factors for several non-malaria antigens may
signal that knowledge and practice of malaria transmission and prevention activities may be a proxy for
practicing general health prevention behaviors.
Overall, the majority of pairwise associations of log-MFI values were positive, indicating that higher logMFI values for most antigens tested for in this sample share predictors and the direction of the
association. With the exception of the vaccine preventable diseases, for which immune response is more
likely to be an indication of interaction with the healthcare system and preventive behavior, there is an
indication that individuals in this sample are likely to have several cumulative disease exposures. While
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only exposure status and not disease status can be known, the impact of multiple infectious disease
exposure can have serious health and economic impacts on the individual and community levels30.
Limitations
There are several limitations to this analysis. The household survey administered during which the
samples were collected was intended to measure malaria and associated behaviors, and many variables
that would likely be strong predictors of non-mosquito borne diseases such as vaccine status, water
source, food handling practices, and intervention coverage such as MDA administration were not
included in the survey. Second, while seroprevalence studies can be used to gain information about
pathogen exposure, they cannot provide information about whether these exposures happened at the same
time, or even if exposure was associated with illness, limiting the ability to make inferences about cooccurrence of active infections. While the use of log-MFI values, rather than assigning a binary cutoff for
seropositive and seronegative reduces misclassification bias due to challenges in determining appropriate
cutoff values, log-MFI is not as easily interpretable, and the range of values vary by antigen.
Conclusions
Multiplex assays coupled with cross-sectional survey data regarding practices, socioeconomic indicators,
and access and use of healthcare services can provide insights about common predictors that may be
associated with exposure to multiple pathogens. By understanding the epidemiology of several pathogens
at once, public health practitioners can target the most common predictors of exposure to diseases in an
area making more efficient and effective public health interventions in resource-limited settings.
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Abstract
Background
Routine assessment of artemisinin-based combination therapies (ACTs) efficacy is critical for the early
detection of antimalarial resistance. We evaluated the efficacy of ACTs recommended for treatment of
uncomplicated malaria in five sites in Democratic Republic of the Congo (DRC): artemether-lumefantrine
(AL), artesunate-amodiaquine (ASAQ), and dihydroartemisinin-piperaquine (DP).
Methods
Children aged 6-59 months with confirmed P. falciparum malaria were treated with one of three ACTs
and monitored. The primary endpoints were uncorrected and PCR-corrected 28-day (AL & ASAQ) or 42day (DP) cumulative efficacy. Molecular markers of resistance were investigated.
Results
Uncorrected efficacy estimates ranged from 63% to 88% for AL, 73% to 100% for ASAQ, and 56% to
91% for DP. PCR-corrected efficacy estimates ranged from 86% to 98% for AL, 91% to 100% for ASAQ
and 84% to 100% for DP. No pfk13 mutations previously found to be associated with ACT resistance
were observed. Statistically significant associations were found between certain pfmdr1 and pfcrt
genotypes and treatment outcome.
Conclusions
There is evidence of efficacy below the 90% cutoff recommended by WHO to consider a change in firstline treatment recommendations of two ACTs in one site each. Confirmation of these findings in future
therapeutic efficacy monitoring in DRC is warranted.
Abstract word count: 199
Key words: Antimalarial, P. falciparum, efficacy, resistance, malaria, DRC
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Introduction
Democratic Republic of the Congo (DRC) accounts for an estimated 12% of the malaria morbidity and
11% of malaria mortality globally, with 25 million reported malaria cases and 46,000 deaths annually[1].
In 2005, artemisinin-based combination therapies (ACTs) were introduced in DRC for the treatment of
uncomplicated malaria as recommended by the World Health Organization (WHO) to prevent or delay
resistance to artemisinin derivatives and partner drugs[2]. Two ACTs, artemether-lumefantrine (AL) and
artesunate-amodiaquine (ASAQ), are used as first-line treatments, and dihydroartemisinin-piperaquine
(DP) is considered as an alternative first-line treatment for uncomplicated Plasmodium falciparum
malaria in DRC. All three ACTs circulate freely in the private sector[3].
WHO recommends the implementation of therapeutic efficacy studies at least every two years in malaria
endemic countries to quickly identify reduced sensitivity to ACTs[4]. Early identification of waning
efficacy of a drug may inform DRC national malaria control program (NMCP) policy for malaria
treatment. Recent studies have demonstrated that AL, ASAQ, and DP are efficacious in DRC, with perprotocol PCR-corrected efficacies of over 90% in studies conducted between 2015–2017[5,6].
In addition to monitoring ACT efficacy, therapeutic efficacy studies may monitor molecular markers of
antimalarial resistance among Plasmodium falciparum parasites. Specific polymorphisms in the propeller
domain of the pfkelch13 (pfk13) gene[7] have been associated with artemisinin resistance, a finding
described in Southeast Asia[8] and polymorphisms identified in one country in sub-Saharan Africa[9].
Decreased susceptibility to lumefantrine and amodiaquine has been associated with polymorphisms in the
gene pfmdr1[10] and decreased susceptibility to amodiaquine has been associated with polymorphisms in
the gene pfcrt .
This report will describe the results of a study examining the therapeutic efficacy of three ACTs used for
the treatment of uncomplicated Plasmodium falciparum malaria in five sites in DRC. Prevalence of
molecular markers of resistance to artemisinin derivatives and partner drugs will also be presented.
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Methods
The standard WHO protocol for in vivo therapeutic efficacy studies[4] was followed to assess the efficacy
of AL, ASAQ, and DP in five sentinel sites representing different epidemiologic zones of DRC. Study
recruitment took place from March 2017 to January 2018.
Study sites and population
Three sites in the equatorial zone of DRC were included: Kabondo, in Kisangani in the northern Tshopo
province, where malaria prevalence measured by rapid diagnostic test (RDT) among children 6–59
months old was 52.2% in the 2017–2018 Multiple Indicator Cluster Survey[11]; Mikalayi, in the Kasai
Central province, where malaria prevalence measured by RDT among children 6-59 months old was
45.5%; and Kimpese, in the Kongo Central province next to the border with Angola, where malaria
prevalence measured by RDT among children 6–59 months old was 40.0%. The fourth site, Rutshuru,
located in the mountainous zone next to the border with Rwanda in the North Kivu province of eastern
DRC, where malaria prevalence measured by RDT among children 6-59 months old was 11.4%. The fifth
site, Kapolowe, is in the Haut Katanga province in the southern part of the country, next to the border
with Zambia, and is in the tropical zone, where malaria prevalence measured by RDT among children 659 months old was 42.7%. The national malaria prevalence measured by RDT among children 6-59
months old was 38.5%[11].
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Figure 3.1: Location of antimalarial therapeutic efficacy monitoring sites, Democratic Republic of
the Congo, 2017

Children aged 6–59 months old with uncomplicated Plasmodium falciparum malaria infection were
recruited at participating health centers. A sample size of 88 children per arm per site was targeted and
calculated assuming 5% drug failure, 95% confidence level, 5% precision and the assumption of 20% loss
to follow-up.
Study Procedures
Criteria for inclusion included Plasmodium falciparum infection measured by microscopy with parasite
density between 2,000–200,000 trophozoites per µl, axillary temperature of 37.5°C or higher, ability to
take oral medication, ability to adhere to the study follow-up procedures, declared consent from a parent
or guardian, absence of signs of severe illness, malnutrition, or other illness associated with fever, and
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absence of past allergic reaction to the study medication. Children with severe anemia (hemoglobin
<5g/dl or hematocrit <15%), weighing less than 5kg, taking regular medication contraindicated with the
study medication, or presenting with signs of severe illness were excluded from the study.
Microscopic blood examination was performed by trained microscopists using thick and thin smears on
the same slide to determine parasite species. Two slides were collected for each patient, one for screening
and one for quantification of parasitemia. The slide for screening was stained with 10% Giemsa for 10
minutes and the second with 6% Giemsa for 30 minutes. Quality control of the study slides was carried
out at two levels: first, at each study site by two trained and experienced microscopists and a third in case
of discrepancy. Second, at the end of the study, 10% of slides from each site were also read by the
national malaria reference laboratory located at the Institut National de Recherche Biomédicale.
Study participants were randomly assigned one of three ACTs: ASAQ (Winthrop; Sanofi Aventis, Paris,
France), AL (Coartem, Novartis, Basel, Switzerland), or DP (Eurartesim, Alfasigma, Bologna, Italy).
Weight-based dosage was determined using the WHO malaria treatment guidelines[2]. Medications were
procured by the DRC NMCP and its partners, notably WHO, and underwent quality control at the
laboratory of the Faculty of Pharmaceutical Sciences of the University of Kinshasa (DRC). Medication
was administered on days 0, 1, and 2 under supervision of study staff. AL intake was also accompanied
by the intake of milk and biscuits. All children enrolled in the study were administered paracetamol for
fever management in the first 48 hours after seeking care at the health facility. All doses, including the
evening dose of AL, were observed by a study team member and were observed for 30 minutes after each
dose was administered. Any child who vomited during this 30-minute window received the same dose of
medication and was observed for an additional 30 minutes. In case of vomiting a second time, the child
was removed from the study and given a rescue treatment[12].
There were nine total pre-planned visits in the 42 days of follow-up (day 0, 1, 2, 3, 7, 14, 21, 28, 35, 42).
However, parents and guardians were instructed to return to the study site for any reason, including
sickness or adverse event related to the study medication. A clinical evaluation was performed at all
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follow-up visits. On day 0, medical history and demographic information were recorded in addition to
screening for malnutrition by measuring body weight by Salter or baby scale, brachial circumference, and
checking for the presence of nutritional edema. Hemoglobin was measured on days 0, 14, 28, and 42 by
sampling capillary blood using Hemocue® (Angelholm, Sweden). Parasitological examination was done
by a trained microscopist on all follow-up visits. Capillary blood was collected on Whatman (GE
Healthcare, Chicago, IL) filter paper for PCR-genotyping to differentiate reinfections from recrudescent
infections and characterization of molecular markers of antimalarial resistance on days 0, 7, 14, 21, 28,
35, 42, and unplanned visits. Rescue treatment was administered in case of recurrent parasitemia or severe
illness in accordance with the national case management guidelines[12].
Supervision was organized in each site by the monitor and instructors at the start of the study, once during
recruitment, and at the closure of the study site. A supervision tool was used during each supervision visit
and feedback was provided to study staff if any inconsistency in enrollment or follow-up procedures were
noted.
All study participants were assigned a classification at the end of follow-up. Early treatment failures were
defined as parasitemia higher on day 2 than on day 0, parasitemia on day 3 with fever, parasitemia on day
3 of ≥ 25% of the count on day 0, or danger signs or severe malaria in the presence of parasitemia on days
1–3. Recurrences were defined as recurrent parasitemia on days 4 through 28 for AL and ASAQ, and on
days 4 through 42 for DP. Adequate clinical and parasitological response (ACPR) was defined as absence
of recurrence on either day 28 (AL and ASAQ) or 42 (DP). Children who were lost to follow-up or met
exclusion criteria during the study were excluded from the analysis.
Adverse events were recorded by using standard forms and shared with the DRC National
Pharmacovigilance Center (CNPV-RDC). Serious adverse events were communicated by the principal
investigator to the CNPV-RDC and the drug manufacturer within 24 hours. Adverse events were defined
as any unfavorable sign, symptom, syndrome or unexpected illness appearing or worsening with the use
of the study medication. Serious adverse events were defined as any medical occurrence with use of the
71 of 107

LF Moriarty
study medication that resulted in death or was life threatening, required hospitalization, or resulted in
significant or persistent disability.
Molecular analysis
Molecular analyses were performed at the U.S. Centers for Disease Control and Prevention (CDC)
Malaria Laboratory in Atlanta, GA. Genomic DNA extraction from dried blood spots collected on day of
enrollment and day of recurrence was performed using the QIAamp blood minikit (Qiagen Inc., Hilden,
Germany) following the manufacturer’s instructions. PET-PCR was used to confirm Plasmodium
infection and species[13].
The analysis of seven neutral microsatellites was used to distinguish reinfections from recrudescence
among study participants classified with recurrent infection. Fragment lengths from day 0 and day of
recurrence samples were measured after amplification of seven neutral microsatellite loci over six
chromosomes by non-nested or semi-nested PCR using previously described methods[14,15].
Sanger sequencing was used to investigate pfk13, pfcrt, and pfmdr1 single nucleotide polymorphisms
(SNPs) on day 0 and day of recurrence samples for all classified recurences. Polymorphisms within
codons 389–649 of the propeller domain region of pfk13[16], codons 86, 184, 1034, 1042, and 1246 of
pfmdr1, and within codons 72-76 of pfcrt were analyzed. SNPs were identified using the Geneious
software package (Biomatters, Inc. San Francisco, CA).
Data management and statistical analysis
Data were entered into a secure study database with independent double entry. Descriptive statistics of
study participants were performed in addition to descriptions of any adverse events. Uncorrected and
PCR-corrected efficacy estimates were calculated using per-protocol and Kaplan-Meier analyses[4].
Uncorrected per-protocol efficacy was calculated per arm and per site, including all recurrences and
ACPR. Those lost to follow-up or excluded from the study were not included in the uncorrected or PCR-
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corrected per-protocol estimates. Participants lost to follow-up or excluded were included until last day of
follow-up in the Kaplan-Meier analysis.
To perform the PCR-corrected per-protocol and Kaplan-Meier analyses, microsatellite data were used to
assign each recurrent parasitemia a posterior probability of recrudescence using a previously used
Bayesian algorithm further validated for this study[17]. Samples for which amplification was not possible
were assigned the average posterior probability of recrudescence from all amplified samples. For the
PCR-corrected per-protocol analysis, the total number of recrudescences was defined as the sum of
probability of recrudescence in all recurrent infections per arm and site. The number of reinfections
equaled the total number of recurrences minus the sum of the posterior probability of recrudescence and
was excluded from the PCR-corrected per-protocol calculation. For the PCR-corrected Kaplan-Meier
analysis, posterior sampling was used to generate Kaplan-Meier estimates and 95% confidence intervals
from the posterior probability of recrudescence. A sensitivity analysis was done to assess the use of a
cutoff approach to distinguish recrudescence vs. reinfection, defining a recrudescence as above or equal to
a predetermined number of matches over the seven loci vs. the use of the sum of probabilities of
recrudescence to tally the number of recrudescences as done to derive the efficacy results in this study.
The combination of SNPs at pfmdr1 codons 86, 184, and 1246 were used to define pfmdr1 haplotypes,
and the combination of SNPs at pfcrt codons 72-76 were used to define pfcrt haplotypes. For mixed
infections, all possible haplotypes (i.e., wild type and mutant) were counted for Pfmdr1 and included in
the analysis. For Pfcrt, the wildtype (CVMNK) and most likely mutant haplotypes were reported for
mixed infections. To investigate differences in pfmdr1 between cleared and uncleared parasites,
haplotypes of day 0 samples of reinfections (cleared infections) were compared to the haplotypes of day
of recurrence samples among recrudescences and reinfections (uncleared infections) using Fisher’s exact
test. Reinfection for day of recurrence were included as “uncleared” infections due to the lack of
susceptibility of parasites to post-treatment prophylaxis[18]. For tabulation, samples with a posterior
probability of recrudescence of ≥50% were defined as a recrudescence and those with a posterior
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probability of <50% were considered reinfections. Multiplicity of infection (MOI) was calculated per site
in samples from those who experienced recurrent infection as the maximum number of SNPs detected
among the seven neutral microsatellite markers.
Microsoft Excel and R version 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria) were used
to perform statistical analyses.
Ethical considerations
The DRC Ethics Committee of the School of Public Health of the University of Kinshasa provided
ethical clearance for the study in DRC. The study protocol was registered in an approved public register
(ClinicalTrials.gov) whose registration number is NCT02940756. Informed consent was available in
French and translated into local languages Lingala, Kikongo, Swahili, and Tshiluba. All patient
information was kept confidential and was known only to the research team. Staff from the Centers for
Disease Control and Prevention (CDC) provided technical assistance[19]; the protocol was approved as a
non-research program evaluation by the Office of the Associate Director for Science, Center for Global
Health at CDC.
Results
A total of 1,356 children were enrolled in the study over the three drug arms and five sites (range per arm:
75 to 96), with 1,271 (93.7%; range 83.1 to 97.9%) reaching a study endpoint. A total of 85 children were
withdrawn or lost to follow-up over all arms. Day 3 slide positivity rates were null in all arms except for
the Kabondo ASAQ arm, where the day 3 slide positivity was 1% (1/81), and the Kabondo DP arm,
where the day 3 slide positivity rate was also 1% (1/74).
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Description of study participants
Table 3.1: Baseline characteristics and enrollment of patients participating in the DRC therapeutic efficacy study, 2017
Site

Kabondo

Drug

Characteristics at day of study enrollment
Age, years
Female, n
Weight (kg)
(mean, sd)
(%)
(mean, sd)

AL (n=89)
2.7 (1.3)
ASAQ (n=84) 2.8 (1.1)
DP (n=89)
2.6 (1.2)
Kapolowe AL (n=96)
2.4 (1.3)
ASAQ (n=94) 2.6 (1.3)
DP (n=96)
2.4 (1.3)
Kimpese AL (n=75)
3.3 (1.3)
ASAQ (n=90) 3.3 (1.3)
DP (n=85)
3.1 (1.2)
Mikalayi AL (n=94)
2.0 (1)
ASAQ (n=92) 2.1 (1.4)
DP (n=94)
2.2 (1.3)
Rutshuru AL (n=93)
2.5 (1.4)
ASAQ (n=91) 2.5 (1.2)
DP (n=94)
2.5 (1.2)
DRC: Democratic Republic of the Congo
sd: standard deviation
AL: artemether lumefantrine
ASAQ: artesunate amodiaquine
DP: dihydroartemisinin piperaquine

37 (41.6)
32 (38.1)
45 (50.6)
52 (54.2)
51 (54.3)
43 (44.8)
38 (50.7)
44 (48.9)
28 (32.9)
43 (45.7)
45 (48.9)
52 (55.3)
44 (47.3)
39 (42.9)
56 (59.6)

12.3 (3.2)
12.7 (2.7)
11.9 (2.9)
11.9 (3.1)
12 (3.1)
11.9 (3.4)
14 (4.4)
13.7 (3.5)
12.9 (3.2)
10.7 (2.8)
10.5 (3.1)
11.6 (8.7)
11.1 (3.2)
11.3 (2.9)
11.4 (3.3)

Parasitemia, geometric
mean, parasites/µL
(range)
19944 (2046, 179760)
27450 (2272, 195564)
22436 (4078, 168915)
39426 (2039, 192554)
36842 (2032, 207761)
33949 (2095, 198059)
17625 (2008, 199446)
21520 (2015, 199538)
22189 (2080, 199095)
25437 (2016, 163200)
23619 (1050, 179428)
24995 (1454, 188800)
27273 (2088, 195246)
32539 (2000, 301900)
32613 (2679, 198579)

Enrollment and follow-up
Lost to follow
Excluded, n (%)
up, n (%)

Reached study
endpoint, n (%)

6 (6.7)
3 (3.6)
15 (16.9)
2 (2.1)
2 (2.1)
3 (3.1)
1 (1.3)
8 (8.9)
4 (4.7)
2 (2.1)
2 (2.2)
4 (4.3)
1 (1.1)
1 (1.1)
0 (0)

83 (93.3)
81 (96.4)
74 (83.1)
93 (96.9)
89 (94.7)
92 (95.8)
74 (98.7)
82 (91.1)
81 (95.3)
92 (97.9)
84 (91.3)
88 (93.6)
89 (95.7)
82 (90.1)
87 (92.6)

0 (0)
0 (0)
0 (0)
1 (1.0)
3 (3.2)
1 (1.0)
0 (0)
0 (0)
0 (0)
0 (0)
6 (6.6)
2 (2.1)
3 (3.2)
8 (8.8)
7 (7.4)
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Efficacy
There were 268 recurrent infections, including no early treatment failures observed in any arm. The mean
MOI among all day 0 and day of recurrence samples among recurrent infections was 2.0 (standard
deviation, 0.83, range 1, 5) (Supplemental Figure 1).
Uncorrected 28-day cumulative efficacy for AL ranged from 63% (95% CI 55, 74) in Mikalayi to 88%
(95% CI 82, 95) in Kabondo. PCR-corrected 28-day cumulative efficacy for AL ranged from 86% (95%
CI 79, 93) in Mikalayi to 98% (95% CI 95, 100) in Kabondo.
Uncorrected 28-day cumulative efficacy for ASAQ ranged from 73% (95% CI 64, 83) in Rutshuru to
100% (95% CI 100, 100) in Kabondo. PCR-corrected 28-day cumulative efficacy for ASAQ ranged from
91% (95% CI 85, 98) in Rutshuru, to 100% (95% CI 100, 100) in Kabondo and Kapolowe.
Uncorrected 28-day cumulative efficacy for DP ranged from 75% (95% CI 67, 85) in Rutshuru to 99%
(95% CI 97, 100) in Kimpese. PCR-corrected 28-day cumulative efficacy for DP ranged from 97% (95%
CI 93, 100) in Rutshuru to 100% (95% CI 100, 100) in Kabondo. Uncorrected 42-day cumulative efficacy
for DP ranged from 56% (95% CI 47, 67) in Mikalayi to 91% (95% CI 85, 98) in Kabondo. PCRcorrected 42-day cumulative efficacy for DP ranged from 84% (95% CI 75, 93) in Mikalayi to 100%
(95% CI 99, 100) in Kabondo.
The sensitivity analysis examining the use of a cutoff approach based on number of matches at each loci
yielded highly variable failure rates for each drug dependent on the cutoff used, influenced by the
relatively high number of intermediate values of posterior probability of recrudescence for each instance
of recurrent parasitemia (Supplemental Figures 3.2 & 3.3).
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Table 3.2: Classification of patients with the outcome of late recurrence, DRC therapeutic efficacy study, 2017
AL
(n=83)
0

Kabondo
ASAQ DP
(n=81) (n=74)
0
0

AL
(n=93)
0

Kapolowe
ASAQ DP
(n=89) (n=92)
0
0

AL
(n=74)
0

Kimpese
ASAQ DP
(n=82) (n=81)
0
0

Early treatment
failure
Late recurrence 10
0
7
23
0
33
11
6
Recrudescence1 1
0
0
4
0
6
2
0
Day 7-13
0
0
0
0
0
0
0
0
Day 14-21
1
0
0
1
0
1
1
0
Day 22-28
0
0
0
3
0
1
1
0
Day 29-35
0
2
Day 36-42
0
2
Reinfection
9
0
7
19
0
27
9
6
Day 7-13
0
0
0
0
0
0
0
1
Day 14-21
1
0
1
10
0
1
7
1
Day 22-28
8
0
0
9
0
7
2
4
Day 29-35
4
11
Day 36-42
2
8
ACPR
73
81
67
70
89
59
63
74
1
Recrudescence defined as a late recurrence with a posterior probability of recrudescence ≥ 0.5
DRC: Democratic Republic of the Congo
AL: artemether lumefantrine
ASAQ: artesunate amodiaquine
DP: dihydroartemisinin piperaquine
ACPR: adequate clinical and parasitological response

8
0
0
0
0
0
0
8
0
1
7
0
0
73

AL
(n=92)
0
34
14
0
3
11
20
0
7
13
58

Mikalayi
ASAQ DP
(n=84) (n=88)
0
0
20
3
0
2
1
17
0
8
9
64

39
12
0
1
1
6
4
27
0
3
10
8
6
49

AL
(n=89)
0
18
3
0
2
1
15
0
4
11
71

Rutshuru
ASAQ DP
(n=82) (n=87)
0
0
23
6
0
1
5
17
0
12
5
59

36
3
0
1
1
1
0
34
0
9
11
9
5
51
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Table 3.3: Therapeutic efficacy of three artemisinin-based combination therapies at five monitoring sites, Democratic Republic of the
Congo, 2017
Kaplan-Meier
Per-protocol
Uncorrected % (95% CI)
PCR-corrected % (95% CI)a
Uncorrected % (95% CI)
PCR-corrected % (95% CI)a
Site
Drug
28 days
42 days
28 days
42 days
28 days
42 days
28 days
42 days
Kabondo
AL
88 (82, 95)
98 (95, 100)
88 (79, 94)
98 (92, 100)
ASAQ 100 (100–100)
100 (100, 100)
100 (96, 100)
100 (96, 100)
DP
99 (96, 100)
91 (85, 98)
100 (100, 100) 100 (99, 100) 99 (93, 100)
91 (81, 96)
100 (95, 100) 100 (94, 100)
Kapolowe AL
76 (68, 85)
94 (89, 99)
75 (65, 84)
93 (84, 97)
ASAQ 100 (100, 100)
100 (100, 100)
100 (96, 100)
100 (96, 100)
DP
89 (83, 96)
64 (56, 75)
98 (94, 100)
93 (87, 99)
89 (81, 95)
64 (53, 74)
96 (90, 99)
91 (82, 97)
Kimpese
AL
85 (78, 94)
96 (92, 100)
85 (75, 92)
96 (88, 99)
ASAQ 93 (88, 99)
99 (98, 100)
93 (84, 97)
100 (95, 100)
DP
99 (97, 100)
90 (84, 97)
100 (100, 100) 100 (99, 100) 99 (93, 100)
90 (81, 96)
100 (96, 100) 100 (95, 100)
Mikalayi
AL
63 (55, 74)
86 (79, 93)
63 (52, 73)
82 (71, 90)
ASAQ 77 (69, 86)
96 (91, 99)
76 (66, 85)
95 (86, 99)
DP
83 (76.91)
56 (47, 67)
97 (94, 100)
84 (75, 93)
83 (73, 90)
56 (45, 66)
88 (89, 94)
80 (68, 89)
Rutshuru
AL
80 (72, 89)
96 (92, 100)
80 (70, 88)
96 (88, 99)
ASAQ 73 (64, 83)
91 (85, 98)
72 (61, 81)
91 (81, 97)
DP
75 (67, 85)
59 (50, 70)
97 (93, 100)
95 (90, 100)
75 (65, 84)
59 (48, 69)
99 (92, 100)
93 (83, 98)
Bold indicates point estimate of PCR-corrected efficacy <90%
a
Number of treatment failures calculated as the sum of posterior probabilities of recrudescence
CI: confidence interval
AL: artemether-lumefantrine
ASAQ: artesunate-amodiaquine
DP: dihydroartemisinin-piperaquine
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Safety
Among the 1,356 children enrolled in the study, five serious adverse events were reported including two
deaths (one in the Rutshuru DP arm and one in the Mikalayi ASAQ arm). Three instances of respiratory
distress were reported among participants in the Rutshuru DP arm. After clinical assessment, it was
concluded that it was unlikely that these events were associated with the study drug or concomitant
medication.
Molecular markers of antimalarial resistance
There were 577 dried blood spots available for analysis of molecular markers of antimalarial resistance.
Samples taken on day 0 from participants with recrudescent infections (n=54) were excluded from the
analysis to avoid double counting a parasite.
pfk13
A total of 251/263 day 0 reinfections were successfully sequenced for pfk13 (95%) (cleared initial
infection), and 235/260 (90%) samples were successfully sequenced from day of recurrence samples
(uncleared infections).
Most samples (96%) included in the analysis were wild type for pfk13. Synonymous mutations (P417P,
C469C, R471R, S477S, T478T, G496G, Y511Y, R539R, S576S) were found in 17 (3%) samples, and a
non-synonymous mutation, S477Y, was observed in one day of recurrence sample in the DP arm.
pfmdr1
A total of 466 dried blood spots from those in the AL and ASAQ arms were included for analysis. A total
of 204/206 (99%) day 0 reinfections were successfully sequenced (cleared initial infection), and 258/260
(99%) samples were successfully sequenced from day of recurrence samples (uncleared infections).
More than half of the samples analyzed had the N86 pfmdr1 SNP (263/462, 57%). Eleven percent
(52/462) had mixed N/Y, and 32% (147/462) had the 86Y SNP. More than half (268/462, 58%) carried
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the Y184 pfmdr1 SNP, with 102 (22%) with mixed Y/F, and 92 (20%) with the 184F pfmdr1 SNP. Most
samples (379/462, 82%) carried the D1246 pfmdr1 SNP, 35 (8%) had mixed D/Y, and 48 (10%) carried
the 1246Y SNP. The most common pfmdr1 haplotypes were NYD (N86, Y184, D1246) (50%), NFD
(N86, 184F, D1246) (31%), and YYD (86Y, Y184, 1246Y) (28%; percentages total > 100% due to mixed
infections). In the AL arm, there was a statistically significant increased risk of failure in samples carrying
the N86 versus the 86Y pfmdr1 SNP (p=.007, Fisher’s exact test). Also in the AL arms, there was a
statistically significant increased risk of treatment failure among samples with the NYD compared to the
YFD haplotype (p= 0.003, Fisher’s exact test). No statistically significant associations were found
between treatment outcome and pfmdr1 SNP or haplotypes in any other treatment arm.
Pfcrt
Investigation of pfcrt SNPs was performed in samples from the ASAQ arms only. There were 85 samples
included in the analysis. A total of 38 samples from day 0 of those who would experience a reinfection
were successfully sequenced (100%), and 47 samples from day of recurrence were successfully
sequenced (100%).
At codon positions 72 and 73, all samples were wild type (C and V respectively). Most samples were
found to have the 74I (88%), 75E, (87%), and 76T (88%) pfcrt SNPs, and the most common haplotype
among samples analyzed was CVIET (C72, V73, 74I, 75E, 76T) (88%). There was a statistically
significant increased risk of treatment failure among those with the 75E versus the N75 SNP (p= 0.042,
Fisher’s exact test), and having the 76T versus the K76 SNP (p= 0.013, Fisher’s exact test). There was
also a statistically significant increased risk of treatment failure among samples with the CVIET versus
the CVMNK haplotype (p= 0.013, Fisher’s exact test) (Supplemental Tables 3.1-3.3).
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Table 3.4: Molecular markers of resistance, all drug arms, Democratic Republic of the Congo therapeutic efficacy study, 2017

pfk13
Successfully sequenced
Wild type
Synonymousa
Non-synonymous b
pfmdr1c
Successfully sequenced
N86
86N/Y
86Y
Y184
184Y/F
184F
D1246
1246D/Y
1246Y
NYD
NFD
NFY
NYY
YFD
YFY
YYD
YYY
pfcrtd, e
Successfully sequenced
M74
74M/I

All samples

Reinfection Day 0

Recrudescence + Reinfection Day of
recurrence

486/523 (93%)
468 (96%)
17 (3%)
1 (0.2%)

251/263 (95%)
244 (97%)
7 (3%)
0 (0%)

235/260 (90%)
224 (95%)
10 (4%)
1 (0.4%)

462/466 (99.1%)
263 (57%)
52 (11%)
147 (32%)
268 (58%)
102 (22%)
92 (20%)
379 (82%)
35 (8%)
48 (10%)
232 (50%)
141 (31%)
20 (4%)
31 (7%)
69 (15%)
0 (0%)
130 (28%)
20 (4%)

204/206 (99%)
109 (53%)
26 (13%)
69 (34%)
119 (58%)
45 (22%)
40 (20%)
166 (81%)
13 (6%)
25 (12%)
89 (44%)
53 (26%)
7 (3%)
10 (5%)
27 (13%)
0 (0%)
48 (24%)
20 (10%)

258/260
154 (60%)
26 (10%)
78 (30%)
149 (58%)
57 (22%)
52 (20%)
213 (83%)
22 (9%)
23 (9%)
143 (55%)
88 (34%)
13 (5%)
21 (8%)
42 (16%)
0 (0%)
82 (32%)
0 (0%)

85/85 (100%)
8 (9%)
2 (2%)

38/38 (100%)
6 (16%)
2 (5%)

47/47 (100%)
2 (4%)
0 (0%)
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75 (88%)
30 (79%)
45 (96%)
74I
10
(12%)
8
(21%)
2 (4%)
N75
1 (1%)
0 (0%)
1 (2%)
75N/E
74 (87%)
30 (79%)
44 (94%)
75E
9 (11%)
8 (21%)
1 (2%)
K76
1 (1%)
0 (0%)
1 (2%)
76K/T
75 (88%)
30 (79%)
45 (96%)
76T
9 (11%)
8 (21%)
1 (2%)
CVMNK
75
(88%)
30
(79%)
45
(96%)
CVIET
1 (1%)
0 (0%)
1 (2%)
CVMNT
3 (6%)
2 (6%)
1 (2%)
CVINK
a
Synonymous mutations include P417P, C469C, R471R, S477S, T478T, G496G, Y511Y, R539R, S576S,
b
Non-synonymous mutation, S477Y
c
pfmdr1 haplotype constructed according to amino acids at positions 86, 184, and 1246; mixed infections included in numerator for each haplotype
d
pfcrt haplotype constructed according to amino acids at positions 72, 73, 74, 75, and 76; mixed infections included in numerator for each haplotype
e
all samples were wildtype for positions 72 (C) and 73 (D)
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Discussion
This therapeutic efficacy study assessed three ACTs and molecular markers of antimalarial resistance in
five sites representing different epidemiologic zones of DRC. Uncorrected efficacy estimates ranged from
63% to 88% for AL, 73% to 100% for ASAQ (at 28 days), and 56% to 91% for DP (at 42 days). PCRcorrected efficacy estimates ranged from 86% to 98% for AL, 91% to 100% for ASAQ and 84% to 100%
for DP at the aforementioned endpoints. No pfk13 mutations previously found to be associated with ACT
resistance were observed. There were statistically significant associations between certain pfmdr1 and
pfcrt genotypes and haplotypes and treatment outcome in the AL and ASAQ arms, respectively.
There was a significant number of recurrent parasitemia in all arms in the present study, yielding low
uncorrected efficacy estimates for all drugs (but not in each site). The high number of reinfections,
particularly in the AL arm, provide evidence of limited post-treatment prophylaxis resulting in a large
proportion of children being reinfected within 4 weeks of an initial infection. Repeated malaria infection
among young children can result in severe health consequences[20–22].
There were observed efficacies below 90% in two of 15 arms in the study: in the Mikalayi AL and DP
arms. Past studies in DRC have not shown evidence of suboptimal efficacy of these ACTs. In all
estimates except for the 42-day per-protocol estimate for the Mikalayi DP arm, the confidence intervals
spanned above 90% PCR-corrected efficacy. However, in seven additional arms where the point estimate
observed was 90% or above, confidence intervals spanned below the 90% threshold (Kapolowe AL and
DP arms, Kimpese AL arm, Rutshuru AL, ASAQ, and DP arms, and Mikalayi ASAQ arm). The precision
in PCR-corrected estimates can be lost in areas of high-transmission with high rates of reinfection such as
DRC, where up to 34 participants were excluded from the PCR-corrected estimates due to reinfection.
This reduction in sample size limits the ability to make conclusions with certainty about ACT efficacy.
Additionally, in a study conducted in Angola in 2019, one site, Lunda Sul, which is located across the
border not far from Mikalayi showed evidence of AL efficacy <90%[23], raising concerns about the use
of this drug for the region. .
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The proportionally large number of intermediate values of posterior probability of recrudescence derived
from the Bayesian algorithm for interpretation of microsatellite markers molecular correction
demonstrates the complexity of the parasite population in this study. Using a molecular correction method
that accounts for uncertainty of classifications of recurrent parasitemia, rather than a cutoff approach
assigning a number of loci matches to define a recrudescence, is particularly useful in these settings[24].
The lack of observed pfk13 mutations is consistent with the finding that there were no early treatment
failures and a slide positivity rate of almost null in all arms, suggesting that artemisinin derivatives are
effective at initial reduction of parasitemia in all arms and all sites in DRC. However, the molecular
findings suggest that susceptibility to lumefantrine and amodiaquine may be decreasing in DRC. The
findings of this study are consistent with previous evidence of higher risk of treatment failure among
those carrying the pfmdr1 N86 SNP versus the 86Y SNP in the AL arm[10], providing molecular
evidence of reduced susceptibility to lumefantrine in the parasite population in DRC. This outcome is
consistent with the reduced efficacy of AL found in Mikalayi. In the ASAQ arm, we observed a high risk
of recurrent parasitemia among samples with the 76T SNP (and CVIET haplotype) compared with K76
(and CVMNK haplotype), findings congruent with the reduced ASAQ efficacy observed in Rutshuru and
previous studies from other countries [10,25,26].
Limitations
Samples collected on day 0 for participants classified as ACPR were not available for molecular analysis.
Therefore, a proxy, day 0 samples from those who cleared their initial infection but would later
experience a reinfection, was used to evaluate associations between treatment outcome and presence of
SNPs. This may have introduced classification bias into statistical tests performed as there may have been
systematic differences between this group of participants who would go on to be reinfected and those who
were not.
Recommendations and conclusions
Therapeutic efficacy monitoring of three drugs in five sites demonstrate evidence of inadequate efficacy
of AL and DP in one site each in addition to molecular findings of SNPs and haplotypes associated in
84 of 107

LF Moriarty
prior studies with reduced susceptibility to lumefantrine and amodiaquine. Further investigation of these
findings to rule out other reasons for treatment failure, including measurement of drug levels to
investigate potential issues of drug absorption, additional validation of molecular genotyping techniques,
and increased sample size to improve precision of efficacy estimates in this setting with high rates of
reinfection are warranted. Decreased efficacy of ACTs in DRC, which has the second highest number of
Plasmodium falciparum malaria infections in the world, could have a strong negative impact on the fight
against malaria in sub-Saharan Africa.
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Chapter 5: Dissertation Summary and Future Directions in Research
Summary
The three papers in this dissertation described different factors impacting the epidemiology of diseases of
public health importance in Democratic Republic of the Congo (DRC) and Mozambique, two countries in
sub-Saharan Africa that are deeply affected by malaria and other tropical diseases. The first paper
described the spatial distribution of malaria in Nampula Province, Mozambique. The analyses found
evidence that active or recent malaria infection as defined by a positive malaria rapid diagnostic test is
highly prevalent and spatially homogenous. This evidence does not support spatial targeting of
interventions in high transmission areas below the district level.
In the second paper, patterns of comorbidities for infectious diseases were explored in Nampula,
Mozambique. The results of the analysis showed several instances of shared predictors of antibody
responses between many infectious diseases of public health importance, with age, sex, and district as the
most common predictors. By understanding the epidemiology of several pathogens at once, public health
practitioners can target the most common predictors of exposure to diseases in an area making more
efficient and effective public health interventions in resource-limited settings such as Mozambique.
The third paper described the results of an antimalarial therapeutic efficacy study investigating three
artemisinin-based combination therapies (ACTs) recommended for the treatment of uncomplicated
malaria in DRC. The study found evidence of efficacy below the 90% cutoff recommended by WHO to
consider a change in first-line treatment recommendations of two ACTs in one site each. If confirmed in a
subsequent efficacy study, inadequate efficacy of ACTs in a high-transmission country such as DRC can
have substantial impacts on malaria morbidity and mortality. Additionally, the need to re-treat more than
10% of malaria cases due to ineffective malaria treatment will have grave financial impacts on the health
system in a country that treats over 18 million cases of malaria per year.
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Directions for future research
Both in the results of the analyses and limitations, all three papers demonstrated that high quality and
complete data are needed to plan, track, and evaluate interventions targeting malaria and other tropical
diseases. Paper 1 showed that that there are spatial analysis methods available to describe spatial
epidemiology at a very local level. However, household surveys are not always designed with these types
of analyses in mind. As countries continue to drive down malaria transmission in high burden areas, more
granular data collection will inform interventions that will target reservoirs of transmission. Paper 2
demonstrated that multiplex platforms can efficiently provide information about prevalence of antibody
responses for several pathogens. Socioeconomic, behavioral, and health access data can complement
biomarkers and allow for further inference about interventions that may target multiple diseases
responsible for morbidity and mortality at once. Indicators with implications for all diseases to be
analyzed in a multiplex platform such as coverage of interventions such as vaccines or mass drug
administration should be considered in future household surveys. Paper 3 demonstrated that clinical and
molecular data can be analyzed together to paint a complete picture of drug efficacy that can impact
effective malaria case management, one of the most impactful interventions needed to decrease disease
burden in high-transmission settings. Consideration of transmission setting and results of previous
efficacy studies should be included in future study planning and may have implications for sample size,
molecular correction techniques, and additions of other assays such as drug levels.
Collectively, the three studies in this dissertation describe factors that have implications for intervention
planning and disease surveillance in areas with high malaria and other tropical disease burden. Careful
consideration of transmission setting can support more efficient and higher quality data collection and
may allow for intervention design tailored to the local realities that can target multiple diseases of public
health importance.
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Supplemental Table 2.1: Protein amounts & buffer conditions used for the analysis of 39 antigens
plus one control
mg
Protein/ml
beads

Buffer

pH

Fusion

Source

Reference

RVFV N Protein
Norovirus strain
Norwalk
Norovirus strain
Sydney
Norovirus strain St.
Cloud

17

MES/NaCl

5

GST

S. Nichol, CDC, USA

unpublished

30

PBS

7.2

None

Jan Vijne, CDC, USA

unpublished

30

PBS

7.2

None

Jan Vijne, CDC, USA

unpublished

30

PBS

7.2

None

Dengue VLP3
CHIKV E protein
(wt and mutant)

30

PBS

7.2

None

7.5 each

PBS

7.2

None

Jan Vijne, CDC, USA
J. Chang, CDC Ft.
Collins, USA
CTK Biotech, San Diego,
CA

P. vivax MSP1/19
P. falciparum
MSP1/19
P. malariae
MSP1/19

20

MES/NaCl

5

GST

30

MES/NaCl

5

GST

30

MES/NaCl

5

GST

P. ovale MSP1/19

30

MES/NaCl

5

GST

csp (P. falciparum)

30

MES/NaCl

5

None

Wb123

120

PBS

7.2

GST

Bm14

120

7.2

GST

Bm33NS

20

PBS
MES/NaCl
+ 2 M urea

6

GST/HIS

unpublished
Poirier et al., 2016, Bull WHO,
94:817-825
Poirier et al., 2016, Bull WHO,
94:817-825
Plucinski et al., 2018, PLOS
NTDs, e0006278
Plucinski et al., 2018, PLOS
NTDs, e0006278
Plucinski et al., 2018, PLOS
NTDs, e0006278
Plucinski et al., 2018, PLOS
NTDs, e0006278
Plucinski et al., 2018, PLOS
NTDs, e0006278
Plucinski et al., 2018, PLOS
NTDs, e0006278
Plucinski et al., 2018, PLOS
NTDs, e0006278
Plucinski et al., 2018, PLOS
NTDs, e0006278

Antigen

T. Nutman, NIH, USA

Mass. Biological
Laboratories, Boston,
MA
Meridian Life Sciences,
Memphis, TN
Meridian Life Sciences,
Memphis, TN
List Biological
Laboratories, Campbell,
CA

Tetanus

12.5

MES/NaCl

5

None

MeaslesQ

6

MES/NaCl

5

None

Rubella

30

MES/NaCl

5

None

Diphtheria
Cysticercosis
T24H

60

MES/NaCl

5

None

120

MES/NaCl

5

GST

Toxoplasma SAG2

12.5

MES/NaCl

5

GST

Giardia VSP3s

30

MES/NaCl

5

GST

Giardia VSP5
Salmonella LPS B
CHAPS
Salmonella LPS D
CHAPS

30

MES/NaCl
MES/NaCl
+ CHAPS
MES/NaCl
+ CHAPS

5

GST

5

None

5

None

Sigma Chemical Co., St.
Louis, MO
Sigma Chemical Co., St.
Louis, MO

S. mansoni SEA

120

7.2

None

E. Secor, CDC, USA

Strongyloides NIE

20

PBS
PBS + 2M
Urea

7.2

GST

Ascaris Hb

120

PBS

7.2

None

10
10

P. Geldhof, Ghent Univ.,
Belgium

Scobie et al., 2016, CVI,
23:546-554
Njenga et al., 2020, AJTMH,
102:164-176
Feldstein et al., 2020, PLOS
Med, 17:e1003071
Njenga et al., 2020, AJTMH,
102:164-176
Priest et al., 2016, PLOS NTDs,
e0004699
Priest et al., 2015, Epidemiol
Infect, 143:618-630
Priest et al., 2010, CVI,
17:1695-1707
Priest et al., 2010, CVI,
17:1695-1707
Aiemjoy et al., 2020, PLOS
NTDs, 14:e0008647
Aiemjoy et al., 2020, PLOS
NTDs, 14:e0008647
Won et al.,2017, AJTMH,
96:1460-1467
Plucinski et al., 2018, PLOS
NTDs, e0006278
Njenga et al., 2020, AJTMH,
102:164-176
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Cp23

12.5

MES/NaCl

5

GST

Cp17

6.8

MES/NaCl

5

GST

CpP2(100) peptide
ETEC labile TX
Beta subunit

30

MES/NaCl

5

None

30

MES/NaCl

5

None

Campy p18

25

MES/NaCl

5

GST

Campy p39

25

MES/NaCl

5

GST

Trachoma pgp3

120

PBS

7.2

GST

D. Martin, CDC, USA

Trachoma CT694

30

PBS

7.2

GST

D. Martin, CDC, USA

Yaws rp17

15

MES/NaCl

5

GST

D. Martin, CDC, USA

Yaws TmpA

15

PBS

7.2

GST

D. Martin, CDC, USA

GST (Control)

15

MES/NaCl

5

GST

Sigma Chemical Co., St.
Louis, MO

Priest and Moss, 2020, Meth.
Mol. Biol. 2052: 61-85
Priest and Moss, 2020, Meth.
Mol. Biol. 2052: 61-85
Benitez et al., 2011, Vaccine,
29:9239-9245
Arnold et al., 2017, PLOS
NTDs, 11:e0005616
Zambrano et al., 2017, AJTMH,
97:876-887
Zambrano et al., 2017, AJTMH,
97:876-887
Goodhew et al., 2012, PLOS
NTDs, 6:e1873
Goodhew et al., 2012, PLOS
NTDs, 6:e1873
Cooley et al., 2016, J Clin
Microbiol, 54:1321-1325
Cooley et al., 2016, J Clin
Microbiol, 54:1321-1325
Priest and Moss, 2020, Meth.
Mol. Biol. 2052: 61-85
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Supplemental Figures 2.1 – 2.7: Density plots by age group of log-MFI values by antigen, Nampula,
Mozambique 2014
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Supplemental Table 3.1: Molecular markers of resistance and association with treatment outcome, artemether lumefantrine arms, DRC
therapeutic efficacy study, 2017

pfk13
Successfully sequenced
Wild type
Synonymousa
Non-synonymous
pfmdr1a
Successfully sequenced
N86
86N/Y
86Y
Y184
184Y/F
184F
D1246
1246D/Y
1246Y
NYD
NFD
NFY
NYY
YFD
YFY
YYD
YYY
pfcrtb, c
Successfully sequenced
M74
74M/I
74I
N75

All samples

Reinfection Day 0

Recrudescence + Reinfection Day
of recurrence

p-value

87/90 (97%)
85 (98%)
3 (3%)
0 (0%)

42/43 (98%)
41 (98%)
1 (2%)
0 (0%)

45/47 (96%)
43 (96%)
2 (4%)
0 (0%)

Ref
1
NA

81/85 (95%)
15 (19%)
13 (16%)
53 (65%)
49 (60%)
14 (17%)
18 (22%)
51 (63%)
12 (15%)
18 (22%)
17 (21%)
18 (22%)
4 (5%)
5 (6%)
69 (85%)
5 (6%)
40 (49%)
26 (32%)

36/38 (95%)
9 (25%)
6 (17%)
21 (58%)
22 (61%)
6 (17%)
8 (22%)
22 (61%)
5 (14%)
9 (25%)
9 (25%)
8 (22%)
1 (3%)
3 (8%)
27 (75%)
1 (3%)
17 (47%)
13 (36%)

45/47 (96%)
6 (13%)
7 (16%)
32 (71%)
27 (60%)
8 (18%)
10 (22%)
29 (64%)
7 (16%)
9 (20%)
8 (18%)
10 (22%)
3 (7%)
2 (4%)
42 (93%)
4 (9%)
23 (51%)
13 (29%)

Ref
0.725
0.268
Ref
1
1
Ref
1
0.817
Ref
0.870
0.662
1
0.446
0.436
0.663
1

85/85 (100%)
8 (9%)
2 (2%)
75 (88%)
10 (12%)

38/38 (100%)
6 (16%)
2 (5%)
30 (79%)
8 (21%)

47/47 (100%)
2 (4%)
0 (0%)
45 (96%)
2 (4%)

Ref
1
0.128
Ref

100 of 107

1 (1%)
0 (0%)
1 (2%)
75N/E
74 (87%)
30 (79%)
44 (94%)
75E
9 (11%)
8 (21%)
1 (2%)
K76
1 (1%)
0 (0%)
1 (2%)
76K/T
75 (88%)
30 (79%)
45 (96%)
76T
9 (11%)
8 (21%)
1 (2%)
CVMNK
75 (88%)
30 (79%)
45 (96%)
CVIET
1 (1%)
0 (0%)
1 (2%)
CVMNT
3 (6%)
2 (6%)
1 (2%)
CVINK
a
pfmdr1 haplotype constructed according to amino acids at positions 86, 184, and 1246; mixed infections included in numerator for each haplotype
b
pfcrt haplotype constructed according to amino acids at positions 72, 73, 74, 75, and 76; mixed infections included in numerator for each haplotype
c
All samples were wildtype for positions 72 (C) and 73 (V)

0.546
0.042
Ref
0.4
0.013
Ref
0.013
0.400
0.909
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Supplemental Table 3.2: Molecular markers of resistance and association with treatment outcome, artesunate-amodiaquine arms,
Democratic Republic of the Congo therapeutic efficacy study, 2017

Pfk13
Successfully sequenced
Wild type
Synonymousa
Non-synonymous
Pfmdr1b
Successfully sequenced
N86
86N/Y
86Y
Y184
184Y/F
184F
D1246
1246D/Y
1246Y
NYD
NFD
NFY
NYY
YFD
YFY
YYD
YYY
Pfcrtc, d
Successfully sequenced
M74
74M/I
74I
N75

All samples

Reinfection Day 0

Recrudescence + Reinfection Day
of recurrence

p-value

87/90 (97%)
85 (98%)
3 (3%)
0 (0%)

42/43 (98%)
41 (98%)
1 (2%)
0 (0%)

45/47 (96%)
43 (96%)
2 (4%)
0 (0%)

Ref
1
NA

81/85 (95%)
15 (19%)
13 (16%)
53 (65%)
49 (60%)
14 (17%)
18 (22%)
51 (63%)
12 (15%)
18 (22%)
17 (21%)
18 (22%)
4 (5%)
5 (6%)
69 (85%)
5 (6%)
40 (49%)
26 (32%)

36/38 (95%)
9 (25%)
6 (17%)
21 (58%)
22 (61%)
6 (17%)
8 (22%)
22 (61%)
5 (14%)
9 (25%)
9 (25%)
8 (22%)
1 (3%)
3 (8%)
27 (75%)
1 (3%)
17 (47%)
13 (36%)

45/47 (96%)
6 (13%)
7 (16%)
32 (71%)
27 (60%)
8 (18%)
10 (22%)
29 (64%)
7 (16%)
9 (20%)
8 (18%)
10 (22%)
3 (7%)
2 (4%)
42 (93%)
4 (9%)
23 (51%)
13 (29%)

Ref
0.725
0.268
Ref
1
1
Ref
1
0.817
Ref
0.870
0.662
1
0.446
0.436
0.663
1

85/85 (100%)
8 (9%)
2 (2%)
75 (88%)
10 (12%)

38/38 (100%)
6 (16%)
2 (5%)
30 (79%)
8 (21%)

47/47 (100%)
2 (4%)
0 (0%)
45 (96%)
2 (4%)

Ref
1
0.128
Ref
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1 (1%)
0 (0%)
1 (2%)
75N/E
74 (87%)
30 (79%)
44 (94%)
75E
9 (11%)
8 (21%)
1 (2%)
K76
1 (1%)
0 (0%)
1 (2%)
76K/T
75 (88%)
30 (79%)
45 (96%)
76T
9 (11%)
8 (21%)
1 (2%)
CVMNK
75 (88%)
30 (79%)
45 (96%)
CVIET
1 (1%)
0 (0%)
1 (2%)
CVMNT
3 (6%)
2 (6%)
1 (2%)
CVINK
a
Synonymous mutations include P417P, C469C, R471R, S477S, T478T, G496G, Y511Y, R539R, S576S,
b
pfmdr1 haplotype constructed according to amino acids at positions 86, 184, and 1246; mixed infections included in numerator for each haplotype
c
pfcrt haplotype constructed according to amino acids at positions 72, 73, 74, 75, and 76; mixed infections included in numerator for each haplotype
d
all samples were wildtype for positions 72 (C) and 73 (D)

0.546
0.042
Ref
0.4
0.013
Ref
0.013
0.400
0.909
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Supplemental Table 3.3: Molecular markers of resistance and association with treatment outcome, dihydroartemisinin-piperaquine arms,
Democratic Republic of the Congo therapeutic efficacy study, 2017
All samples

Reinfection Day 0

Recrudescence + Reinfection
Day of recurrence

P

pfk13
Successfully
208/224 (93%)
99/102 (97%)
109/122 (89%)
sequenced
199 (96%)
96 (97%)
103 (95%)
Ref
Wild type
8 (4%)
0 (0%)
5 (5%)
0.796
Synonymous
1 (0.5%)
0 (0%)
1 (0.9%)
1
Non-synonymous
a
pfmdr1
Successfully
223/223 (100%)
101/101 (100%)
122/122(100%)
sequenced
57 (56%)
70 (57%)
N86
127 (57%)
Ref
16 (16%)
17 (14%)
86N/Y
33 (15%)
0.859
28 (28%)
35 (29%)
86Y
63 (28%)
1
58 (57%)
55 (45%)
Y184
113 (51%)
Ref
22 (22%)
38 (31%)
184Y/F
60 (27%)
0.092
21 (21%)
29 (24%)
184F
50 (22%)
0.353
84
(83%)
104
(85%)
D1246
188 (84%)
Ref
2 (2%)
5 (4%)
1246D/Y
7 (3%)
0.662
15 (15%)
13 (11%)
1246Y
28 (13%)
0.497
53
(52%)
65
(53%)
NYD
118 (53%)
Ref
35 (35%)
46 (38%)
NFD
81 (36%)
0.927
4 (4%)
7 (6%)
NFY
11 (5%)
0.828
5 (5%)
6 (5%)
NYY
11 (5%)
1
34
(34%)
37
(30%)
YFD
71 (32%)
0.805
3 (3%)
6 (5%)
YFY
9 (4%)
0.755
25 (25%)
34 (28%)
YYD
59 (26%)
0.874
15 (15%)
13 (11%)
YYY
28 (13%)
0.538
a
pfmdr1 haplotype constructed according to amino acids at positions 86, 184, and 1246; mixed infections included in numerator for each haplotype
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Supplemental Figure 3.1: Multiplicity of infection of day 0 and day of recurrence samples from treatment failures as determined by the
maximum number of alleles detected among seven neutral microsatellite markers, Democratic Republic of the Congo therapeutic efficacy
study, 2017
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Supplemental Figure 3.2: Histogram of posterior probability of recrudescence of all late recurrences for which the probability of
recrudescence is over 0% (n=114)

The sum posterior probability of recrudescence was 57. There were 54 samples with a posterior probability of recrudescence of .5 or higher (and
labeled as a recrudescence). The mean posterior probability of recrudescence was 0.04 (standard deviation= 0.17). Among late failures for which
the posterior probability of recrudescence was >0 (n=114, 42.5%), the mean posterior probability of recrudescence was 0.49 (standard deviation=
0.37)
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Supplemental Figure 3.3: Assessment of the use of different cutoffs of posterior probability of recrudescence derived using a Bayesian
algorithm for interpreting microsatellite data for molecular correction, Democratic Republic of the Congo therapeutic efficacy study,
2017

Failure rate estimates obtained using the Bayesian analysis algorithm for artemether lumefantrine, artesunate amodiaquine, and dihydroartemisinin
piperaquine. The failure rate derived by summing the posterior probability of recrudescence for each arm is denoted in each plot by a horizontal
gray line. The cutoff for posterior probability at which a recurrence was classified as a recrudescence varied between ≥0.1 and 1.
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